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ABSTRACT 
Background: The use of psychoactive substances among young people, in recreational 
spaces, has been a subject of growing concern. The uncontrolled consumption of these 
substances, associated to risk behaviors, morbility and morbidity, corresponds to a heavy 
burden for the modern society.  
Objective: The main objective of this study was to analyze the drug abuse patterns in 
Coimbra recreational nightlife. 
 Methods: The study was applied in the form of the questionnaire and the collection of 
biological samples from volunteers gathered at nighttime recreational spaces in Coimbra. 
Each blood and oral fluid sample was qualitatively and quantitatively analyzed according 
to each psychoactive substance reported to be used by the interviewed volunteer. Ethanol 
was also evaluated in exhaled air and oral fluid. A GC-MS methodology was developed 
for the measurement of Δ9-tetrahydrocannabinol (THC), and standard methods were used 
for the other psychoactive substances analyzed. The data were gathered by a non-
randomized process of accidental sampling, and quantitative analyzes using the statistics 
tests of Mann-Whitney, Kruskal-Wallis, Pearson Chi-Square, Odd’s Ratio. 
Results: 78 young adults, between 18 to 30 years, participated in the study. 26,92% were 
females and 73,08% males. The majority of them were students (75,64%). Alcohol was 
the psychoactive substance more used (87,2%), followed by tobacco (64,1%), cannabis 
(19,2%), cocaine and amphetamines (2,6%) and finally LSD and smartshop substances 
(1,3%). Males used more psychoactive substances than females, both in quantity and in 
diversity. In relation to risk behaviors or health problems, the cocaine users had the 
highest risk of both types of problems, following cannabis, alcohol and finally tobacco. 
Relatively to biological samples, the ethanol and Δ9-THC were the compounds 
quantitatively analyzed in this study due to their high frequency. Ethanol was the 
substance that had more discordance, as compared to the surveys. The results of Δ9-
THC had more concordance with answers of the surveys. 
Conclusion: Alcohol, tobacco and cannabis were the psychoactive substances more 
used in recreational spaces. Alcohol is the major substance used among young people, 
usually in an excessive way.  Exhaled air reveal to be the best method for analyzing 
ethanol. The Δ9-THC method validated in the present study, showed to be selective, 
linear, efficient, and precise.   
 
 
Keywords: psychoactive substances, alcohol, THC, recreational nightlife. 
VIII 
 
RESUMO 
Introdução: O consumo de substâncias psicoativas entre jovens, em espaços de lazer, 
tem sido um tema de crescente preocupação. O consumo incontrolado destas 
substâncias, associadas a comportamentos de risco, morbilidade e morbidade constituem 
uma tarefa árdua para a sociedade moderna. 
Objetivo: O objetivo principal deste estudo foi analisar os padrões de consumo 
recreativo, de substâncias psicoativas, na cidade de Coimbra.  
Métodos: O estudo foi efetuado sob a forma de um questionário acompanhado de uma 
amostra biológica, colhida a jovens voluntários que se encontravam em espaços 
recreativos noturnos, na cidade de Coimbra. Cada amostra de sangue e fluido oral foi 
qualitativamente e quantitativamente analisada de acordo com o tipo de substância 
psicoativa consumida, reportada pelo participante. O etanol foi também colhido sob a 
forma de ar exalado e fluido oral. Para analisar Δ9-tetrahydrocannabinol desenvolveu-se 
uma metodologia analítica, enquanto que as restantes substâncias foram analisadas 
segundo metodologias padrão. A recolha de dados foi efetuada segundo um processo 
não aleatório de amostra acidental, e a sua análise foi realizada quantitativamente 
recorrendo a testes estatísticos de Mann-Whitney, Kruskal-Wallis, Pearson Chi-Square e 
Odd’s Ratio. 
Resultados: 78 jovens adultos, entre 18 e 30 anos, participaram neste estudo. 26,92% 
eram do género feminino e 73,08% do género masculino. A maioria dos participantes 
eram estudantes (75,64%). O álcool foi a substância psicoativa mais consumida (87,2%), 
seguindo o tabaco (64,1%), canábis (19,2%), cocaína e anfetaminas (2,6%) e finalmente 
LSD e substâncias vendidas em smartshop (1,3%). Os participantes do género masculino 
consomem mais substâncias psicoativas do que os do género feminino, tanto em 
quantidade como em diversidade. Em relação aos riscos comportamentais ou de saúde, 
os consumidores de cocaína apresentavam maior risco de possuírem ambos os 
problemas, seguindo os consumidores de cannabis, álcool e por último tabaco. 
Relativamente às amostras biológicas, o etanol e o Δ9-THC foram as substâncias 
analisadas quantitativamente neste estudo, devido á sua maior frequência. O etanol foi a 
substância que teve maior discordância, quando comparado com as respostas dos 
questionário, enquanto que os resultados do Δ9-THC mostraram-se mais concordantes. 
Conclusão: Álcool, tabaco e cannabis são as substâncias mais consumidas em espaços 
recreativos noturnos. O álcool é a substancia mais consumida pelos jovens de uma forma 
exacerbada. A análise ao álcool por ar exalado foi aquele que obteve resultados mais 
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fidedignos. O método de Δ9-THC validado neste estudo mostrou ser seletivo, linear, 
eficiente e preciso. 
 
 
Palavras-chave: Substâncias psicoativas, álcool, THC, ambiente recreativo noturno 
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1. Drug use among young people 
 In the last few years, most of the consumption of alcohol and illicit drugs among 
young people in Europe, occurs in night-time recreational activities, typically with friends, 
either in formal recreational settings such as pubs, bars and nightclubs, or in informal 
settings such as on the street and at home. Much of party-goers young people’s drug use 
occurs on weekends and during holiday periods (Calafat et al., 2012). A wide range of 
diverse studies have shown that the levels of drug use among young people are higher in 
adolescents frequenting night clubs than among young people in the general population 
(Figure 1) (EMCDDA, 2010).The annual European Report (EMCDDA) shows that high 
levels of cocaine use occurs in regular attendees in clubs and other recreational settings. 
In 2010, 24% of visitors to pubs in Amsterdam were cocaine users. In Czech Republic, 
more than 1000 respondents to a online questionnaire, 29% reported having used cocaine 
in the last 12 months (Figure 1) (EMCDDA, 2012).  
 Cannabis is another drug very common among adolescents. An estimated 15.4 
million young Europeans between 15 to 34 years (11.7% of this age group) used cannabis 
in the last year, together with alcohol, in nightlife (EMCDDA, 2013). 
 
 
Figure 1. Proportion of 16 to 24 year olds reporting use of the most prevalent drugs in the 
last year, by frequency of nightclub visits (adapted from EMCDDA, 2012) 
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. In fact, night recreational settings have been growing importance in young people’s 
life, determining lifestyles and legitimizing behaviors considered necessary for them to 
experience fun and immediate pleasure. For many adolescents and young adults, fun 
means being in fashion places, with friends, and enjoys activities related to music and 
dance. However, in the last few years the recreation nightlife has an intrinsic link with the 
alcohol and other psychoactive substances. Consequently its use in recreational 
environments is currently so high that these contexts are considered risk factors for 
consumption (Lomba et al., 2011). Nowadays, for the majority of young people who 
participate in recreational environments, substance use are almost the norm. Young 
Europeans are constructing a new pattern of entertainment, in which going out with 
friends, mainly on weekends, means drink a lot of alcohol, use drugs, make new 
experiences, to escape from the social constraints of the rest of the week (Calafat et al., 
2003). As recreational settings are increasingly attractive (hegemonic model), almost all 
focused on psychoactive substances, increasing the risk to individual and collective health 
and safety, urgent strategies centered on person and self-control should be implemented, 
once to reduce damage becomes unfeasible. On the other hand, society (parents, 
institutions and authorities), are gradually assuming the harm related to these contexts as 
an inevitable consequence of this form of youth fun, devaluing losses in health as well as 
costs of anti-social behavior and impact that all this might have on the youth future 
(Calafat, et al., 2004).However, the use of drugs in these recreational places, has been 
associated with other risk behaviors. At present, violence and use of alcohol and other 
drugs occurs frequently in recreational settings. The peak time for violent offences is 
weekend nights and around pubs and clubs. In many countries the majority of violent 
assaults take place around a pub or club, and almost half of all violence and disorder-
related incidents occur on weekend nights (Calafat et al., 2011). Many studies relate 
violence occurring in nightlife environments, and the use of alcohol and/or illegal drugs. 
One particularly study shows that 5.2% of the youngsters who go out at night carrying 
weapons, were involved in polydrug use. Another interesting result is that 11.6% of 
youngsters attacked or threatened with a weapon, were involved in rows or argument 
related to substance use. Finally 23% of the youngsters participating in fights, were also 
involved in rows or arguments related to substance use (Blay et al., 2010). These studies 
confirm that prevention should be taken especially in problematic young people who 
engage in polydrug use and who often have fights related to drug consumption. 
 Another risk behavior, associated with the use of psychoactive substances among 
young people in night recreational settings, is sexual risk behavior. In Coimbra, it was 
recently accomplished a survey where were selected teenagers, in the recreational 
settings of Coimbra. Among these teenagers, 64,52% experienced sex under the effects 
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of drugs, 40,33% never/seldom used a condom and 9,64% admitted not having used a 
condom due to being “drunk” or “stoned”. In the same study, 14,60% of these teenagers 
had engaged in sexual activity due to the consumption of drugs and alcohol, having  
regretted it later, and 26,61% undertook medical tests for STIs (Sexually Transmitted 
Infections) (Lomba et al., 2008). Another issue that is in vogue related with drugs and 
sexual behaviors is the consumption of drugs for increasing the sexual performance. 
Some young people use alcohol and other drugs in nightlife, with the proposal to find a 
specific effect on sexuality. The most popular drug used by young people to initiate the 
sexual encounter, for more unusual or the “hottest” experiences, to increase arousal, and 
to prolong sex is alcohol, followed by cocaine. The majority of cases were accomplished 
by women who drank alcohol for increasing arousal, when they want unusual sex or to 
prolong it (Calafat et al., 2008). 
 The road traffic crashes is another risk behavior associated with nightlife alcohol 
and recreational drug use. The big number of road traffic fatalities in Europe, among 
young people, occurs due to the consumption of alcohol, resulting in an estimated of 
17,000 drink driving deaths each year. However, alcohol is not the only substance that 
can affect driving safety. Cannabis, cocaine, amphetamines and other drugs can influence 
driving. Private car was the most frequent form of transport used when going out, 
especially by males and older individuals. Males showed higher levels of drunkenness, 
drug consumption, traffic risk behaviors and traffic crashes than females (Calafat et al., 
2009). 
 Although the consequences of these risk behaviors are increasingly explicit in the 
media, inclusive in education of young people, the number of drug users in new 
generations have maintained all over the years. So, what is happening? Why do young 
people use drugs? 
2.  Why do some people use, abuse, and become dependent on drugs? 
 Many scientists of different areas have frequently asked this question to their audience. 
The diverse audiences focus on this question because they hope that the answer will 
provide clues as to what to do about the problem, as they see and experience it. The 
answer has been investigated, but unfortunately each scientist has different answers. 
Some of them have created models emphasizing neurobiological or psycho-behavioral or 
socio-environmental factors and dynamics. There are some factors that explain this 
question (Pandina and Johnson, 1999). 
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2.1 The nature and the special properties of psychoactive substances 
 Psychoactive substances are substances that have the ability to change an 
individual’s consciousness, mood or thinking processes. These occur because they act in 
the mechanisms of the brain that normally regulate the functions of mood, thoughts and 
motivations. There are many psychoactive substances, however, that could be divided 
into three categories according to their sociolegal status. The first category is used as 
medications for many reasons as: relieving pain, promoting sleep or wakefulness, and 
relieving mood disorders. The second category are illegal substances that are used to 
enjoy or benefit from the psychoactive proprieties of the substance. The third group are 
used as legal substances such as: caffeine, nicotine, tea and alcohol that have stimulant 
proprieties most often used by actual society (Word Health Organization, 2004). 
 In recent decades, clandestine laboratories are synthesizing drugs that are 
chemically and pharmacologically similar to substances that are listed in the Controlled 
Substances Act, but which themselves are not specifically controlled. This kind of drugs 
are called “designer drugs” (Karch, 1998). 
2.2 The outcomes of drug use  
Each drug has different properties that can be used to estimate dependence or to 
classify its potential hazard. A prototype model for comparing relative hazards associated 
with the use of 20 drugs representing six major drug classes, has been described, using 
only two criteria: the quantitative estimates of dependence potential and toxicity (Figure 2) 
(Pandina and Johnson, 1999). 
 
 
 
 
 
Figure 2. Prototype model for comparing relative hazards, using two criteria: potential 
dependence and toxicity (adapted from Pandina and Johnson, 1999). 
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2.3 The dynamics of use behavior  
There is a model created by (Pandina and Johnson, 1999) to explain the most 
common, identifiable sequence and process of the transition to dependency. This model 
divided use patterns in three developmental stages. The first one is the acquisition stage 
where the individuals learn about the drugs, the response capacity of biological tissue to 
drugs, the individual differences and preferences, and the customs of use practices in the 
local life space.  
The second stage is the first experimentation of drugs. Many people experiment 
the drug, however most of them never progress to initiation from the priming phase for 
most drugs (e.g. heroin). This experimentation can be done many times and becomes a 
habit. Thus, use responses become routinized. In this phase, use is under the behavioral 
control of the individual and it does not dominate the response repertoire, bring few  
consequences. When the person becomes dependent on drugs its state reduces 
to maintain homeostatic stability. In this case, use reacquires its centrality in the life of the 
individual and dominates the response repertoire.  
The third stage occurs when there is the obsessive-compulsive behavior. It is 
marked by increased cracking and by the decrease in apparent efficacy of a drug to 
maintain the homeostasis of the organism (Pandina and Johnson, 1999).  
2.4 The individual differences in vulnerabilities 
This topic shows how individual differences determine vulnerability to drug use. 
The motivation for the consumption of drugs is essentially based on biological, 
psychological, and socio-environmental dynamics. The genetic predisposition and the 
neural adaptation (biological), the personality profile and emotional regulation of the user 
(psychological) and the peer-group membership and geopolitical climate (socio-
environmental) are the main reasons that explain the motivational substrata. However 
these factors do not act in the single way and each person is unique. It is the answer that 
explains why some people seem immune or resistant even when they may appear to be 
at high risk (Pandina and Johnson, 1999). 
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3.  Predisposing factors for drug use 
Most studies have identified several predisposing factors associated with drug use 
in adolescents such as: curiosity, obtaining pleasure (hedonism), relaxation of 
psychological tensions, facilitating socialization, peer group pressure and rejection, social 
isolation, family dynamics, low self-esteem, genetic, social, and environmental influences, 
pleasure to face danger (ordalic behaviour) (Kliewer and Murrelle, 2007). However, it is 
difficult to ascertain which risk factors or combination of risk factors are most virulent, 
which are modifiable, and which are specific to drug abuse (Hawkins et al., 1992).  
These factors can be divided into two major categories. The first is related to 
contextual factors (or external factors) that supply legal and normative expectations for 
behavior. The second category correspond to individual and interpersonal environments 
(internal factors) such as family, school and peer group influence, that enhance the risk of 
adolescents initiate or continue the use of drugs (Chakravarthy et al., 2013).  
3.1 Curiosity 
The main internal factor that is associated with drug use in adolescence is 
curiosity. It is the major reason for the first use. Curiosity can increase brand recognition 
and can also prompt experimentation with drug (Wagner and Sundar, 2008). Many 
teenagers have heard about drugs and they are curious to experience them. They have 
heard that drugs can be fun, or make a person feel good sensations. Although their family 
sometimes says exactly the opposite, in this stage of their live they want to see how it 
really feels (Giusti et al., 2002). 
3.2 Peer group influence 
Peer group influence has consistently been found to be among the strongest 
predictors of substance use among young people, more than family influence (Hawkins et 
al., 1992). The best predictors of adolescents' substance use are the proportion of friends 
who are users and their friends' tolerance of use. The behavioral and values structure of 
the peer group, influence the teenager on initial involvement in substance use (Bauman 
and Ennett, 1996). These peer influences amplify the effects of individual sensation 
seeking on affect evaluation, increase the attraction to risky behavior, and reduce the 
perceptions of risk (Romer and Hennessy, 2007).  
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3.3 Ordalic behaviour 
 Ordalic behaviour is defined for some authors as “the person who faces the risk is 
trusting themselves to an external absolute power which will decide the outcome of the 
risky behaviour” (Ranieri, 2011). The use of psychoactive substances and the ordalic 
behaviour is closely related. The fear caused by dangerous situations and the satisfaction 
derived from returning to a state of safety, are the main reasons for drug users, mainly 
adolescents, wanting to be voluntary exposed to danger situations (Ranieri, 2011). 
 In the last few years, the Observatory on Youth and Alcohol has faced this problem 
not only in relation with alcohol but also with the use and abuse of other drugs. An 
interview realized by this organization shows that the majority of risk behaviors among 
young people occurs due to the excessive use of alcohol and drugs. The personal risk 
experiences that are presented in the report refers to: school absenteeism, participation in 
dangerous motorbike driving and frequent traffic accidents, involving dangerous nightlife 
called “life in the borders”, sexual harassment, street violence and competition in driving. 
The largest number of cases answered that they did not know in advance that the 
behaviour they were engaged was risky. The rest of the cases answered that recognized 
risk at a later stage. Depending on the severity of the risk episode, young people try to 
modify their attitudes, beliefs and behaviour. Their decision is also influenced by other 
peer group members with whom they discussed the risky experience and shared their 
feelings (Observatory on Youth and Alcohol, 1998). 
3.4 Hedonism 
Hedonism is a philosophical concept that regards pleasure as the ultimate goal of 
life. For users of drugs seeking pleasure and avoidance of pain, it is the main reason for 
the consumption of psychoactive substances. However “Bentham, one of the chief of 
advocates hedonism, point out that the more we seek pleasure, the less we get it, 
therefore we should not seek pleasure but seek objects that are pleasurable to us” 
(Klerman, 1974). The substances as drugs, with abusive potential fulfill the criteria of such 
objects of pleasure, and the tendency to avoid pain has resulted in a dependent society, 
more and more hedonistic (Ajai and Singh, 1995). Several researches have revealed that 
92% of young students reported use of psychoactive substances for pleasure, indicating 
that this consumption is about hedonism rather than about escaping from problems 
(Newbury-Birch et al., 2000). However this pleasure has not reached with the 
consumption of drugs. The use of psychotropic drugs is slightly negatively related to 
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happiness, especially the use of hard drugs. People who have never tried drugs are half a 
point happier than their compatriots who have used them  (Figure 3) (Veenhoven, 2003). 
 
 
 
Figure 3. Experience with drugs and happiness among young people (adapted from 
Veenhoven, 2003). 
4. Brain Reward System 
4.1 Neuroanatomy of brain reward system 
In 1953, the scientists Olds and Milner discovered that rats learned to return to the 
portions of their environment where they had been given direct electrical stimulation of the 
septal area of the brain. This stimulation was rewarding and the scientists confirmed that 
they could train rats to lever-press, by making short pulse trains of septal brain stimulation 
contingent upon this arbitrary response. Following studies have shown that brain 
stimulation reward establishes and maintains response habits in patterns very analogous 
to those established and maintained by natural rewards such as water, food and sexual 
activity (Wise, 1996). The reason for studying the laboratory reward of brain stimulation is 
to understand the mechanisms of natural rewards and drug rewards. Such as natural 
rewards, the drugs of abuse can also influence the brain stimulation and activate directly 
the reward circuits. This fact helps us to understand better the anatomy and 
neurochemistry of endogenous reward substrates (Wise, 1980).  
The core structure of the brain reward pathway is constituted be two dopamine 
pathways particularly important for the reward system: the mesocortical and the 
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mesolimbic. The mesocortical dopamine pathway projects to multiple cortical areas and it 
is important for many aspects of reward-processing, including hedonic evaluation, 
comparative valuation, and option-assessment. This pathway projects primarily to 
prefrontal, cingulate, and entorhinal cortices in rodents, but to the entire cortical mantle in 
primates (Taber et al., 2012). The mesolimbic dopamine pathway projects primarily from 
ventral tegmental area (VTA -via the medial forebrain bundle) to nucleus accumbens (NA) 
and ventral striatum, secondly projects to other limbic areas such as amygdala, olfactory 
tubercle, septum. This pathway is important for the positive reinforcing effects of both 
natural rewards and drugs of abuse. It is responsible to modulate the activity of the ventral 
striatum, a brain region thought to be involved in converting emotion into motivated action 
and movement (Figure 4) (Koob, 1992). 
 
 
 
Figure 4. Neuroanatomy of the Brain Reward System (Kibiuk, 2012). 
4.2 Molecular physiology of brain reward system 
Neuronal communications in the brain occurs through an electrochemical process, 
with electrical impulses in a neuron modulating the release of neurotransmitters, such as 
dopamine, serotonin, endogenous opiates, N -methyl-Daspartate (NMDA), gamma-
aminobutyric acid (GABA), and acetylcholine. These neurotransmitters diffusing across 
small spaces (called synapse) between adjacent neurons, and binding with proteins 
(called receptors) on the membranes of the adjacent neurons to modulate electrical 
signals and other activities. Then, neurotransmitters are deactivated through metabolism 
or reabsorbed by neurons for reuse (Figure 5) (Kelly et al., 2009). 
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Figure 5. Neurotransmitters mediate communication between adjacent neurons 
(Foundation for Alternative and Integrative Medicine, 2013). 
Psychoactive drugs capitalize on this system, modulating action at the receptor 
level and altering the manner in which neurons regulate neurotransmitters. When drugs 
act on this system effects the hormonal action and then other capacities stay affected 
such as memory, mood, reward, learning and behavior (Kelly et al., 2009). Although drugs 
of abuse act through separate mechanisms and on various locations in the brain reward 
system, all of them increase dopamine levels. Dopamine is a main neurotransmitter of the 
reward pathway, however there are more neurotransmitters such as: serotonin, 
endogenous opiates and GABA that are closely involved in the brain reward pathway and 
also modulate dopamine levels (Esch and Stefano, 2004). 
Psychoactive drugs could act in the central nervous system as agonists or as 
antagonists at the receptors for endogenous chemical messengers. In general, most 
drugs of abuse act as agonist and increase dopamine neurotransmitter levels in the 
reward pathway. For example, cocaine and amphetamines blocks reuptake of dopamine 
and stimulate of release (Wise, 1998). Serotonin neurotransmitter is also affected with the 
use of drugs. This neurotransmitter is mainly involved in the modulation of motivational 
factors and it appears to regulate dopamine release at the nucleus accumbens. The 
consumption of alcohol increases the synaptic availability of serotonin with precursor 
loading, blockade of serotonin reuptake, or blockade of certain serotonin receptor 
subtypes (Koob et al., 1999). GABA is an inhibitory neurotransmitter and has long been 
implicated in the modulation of dopaminergic reward systems, playing a role in the 
mediation of effects of many drugs of abuse such as: alcohol, benzodiazepines and 
barbiturates. These drugs inhibit the release of GABA and release more dopamine in the 
reward system (Wallner et al., 2006). Further neurotransmitters are also affected with the 
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presence of drugs such as: opiates act at receptors for endogenous opioid 
neurotransmitters; nicotine acts at a subclass nicotinic of acetylcholine receptors; 
cannabis acts at receptors an endogenous cannabanoid; phencyclidine acts at the N-
methyl-D-aspartate subtype of glutamate receptor and caffeine acts at adenosine 
receptors. (Koob et al.,1999). 
4.3 Action of drug abuse in brain reward system 
4.3.1 Alcohol 
Alcohol is a drug of use/abuse most widely used in our civilization, however it 
affecting the neurochemical system in diverse areas of the CNS. The severity of its effects 
depends on the dose, genetic susceptibilities and the type of administration (acute or 
chronic). Alcohol causes changes in the brain neurochemical dopamine and 
norepinephrine, especially in VTA (ventral tegmental area). The use of alcohol increases 
the release of dopamine and norepinephrine. The acute administration of alcohol 
increases the release of serotonin within the brain, but chronic administration of this drug 
tends to decrease the amount of serotonin stored in the CNS (Marc and Schuckit, 2006). 
Another neurochemical mechanism that has a major impact on the effects of 
alcohol is GABA. It is the main inhibitory neurotransmitter in the brain and short-term 
alcohol exposure increases the inhibitory effect of GABAA receptors. Alcohol has been 
shown to increase the function of glycine receptors in laboratory and also increase 
inhibitory neurotransmission by increasing the activity of inhibitory neuromodulators such 
as adenosine (Valenzuela, 1997). 
Alcohol induces sedative effects by reducing the major excitatory 
neurotransmitters in the brain, called amino acids aspartate and glutamate, which act in 
NMDA receptors. Acute doses of alcohol inhibit both NMDA and non-NMDA receptor 
activity, potentially resulting in sedation (Valenzuela, 1997). 
4.3.2 Opiates 
 Actually, there are three families of endogenous opioid peptides known: the 
endorphins, enkephalins, and dynorphins, and three major receptors: mu, kappa, and 
delta. All opioids have major impact on the receptor mu, more precisely on mu1 and mu2. 
The activation of these receptors causes analgesia and a feeling reinforcement, having an 
important impact on the neurotransmitter dopamine, in VTA. Opioids can also mediate 
acute effects on NMDA, cholinergic, GABA, cannabinoid, and serotonin systems (Marc 
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and Schuckit, 2006). The use of heroin, the most common opioid of drug abuse, modifies 
the action of dopamine. Once crossing the blood-brain barrier, heroin is converted to 
morphine, which acts as a powerful agonist at the mu opioid receptors subtype. This 
binding inhibits the release of GABA from the nerve terminal, reducing the inhibitory effect 
of GABA on dopaminergic neurons. The increased action of dopaminergic neurons and 
the release of dopamine into the synaptic cause a sustained activation of post-synaptic 
membrane. This continued action leads to the feelings of euphoria associated with heroin 
use (Figure 6). 
 
 
 
Figure 6. The mechanism of action of heroin (adapted from www.cnsforum.com). 
4.3.3 Cannabis 
Cannabis has two neuronal cannabinoid receptors: CB1 and CB2 were recently 
discovered in human cells. Both of these receptor types are coupled through G-proteins, 
negatively to adenylate cyclase and positively to mitogen-activated protein kinase. CB1 
receptors are also coupled to ion channels through G-proteins, negatively to N-type and 
P/Q-type calcium channels and positively to A-type and inwardly rectifying potassium 
channels. Under certain conditions, CB1 receptors may also activate adenylate cyclase 
through G-proteins (Pertwee, 1999). The activation of CB1 receptors produces a cascade 
of effects in the second messenger system within the cells, with an impact on dopamine-
rich areas (located in nucleus accumbens) as well as opioid, gamma aminobutyric acid 
(GABA) and glutamate systems (Marc and Schuckit, 2006). The majority of THC effects 
are mediated through agonistic actions at cannabinoid receptors of the human body. In 
general, when ∆9-THC binds CB1 on pre-synaptic nerve terminals in the brain, activates 
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G- proteins. G-protein activation also activates inwardly, rectifying potassium channels 
and the MAP kinase signalling pathway. This effect on these pathways causes euphoric 
feelings associated with cannabis use (Figure 7) (Grotenhermen, 2006). 
 
 
 
Figure 7. The mechanism of action of cannabis (adapted from www.cnsforum.com). 
4.3.4 Cocaine 
 Cocaine is a strong stimulant drug of abuse derived from  leafs of Erythroxylon 
coca. However the same drug has also local anesthetic properties that may be applied in 
ophthalmology (Dackis and O’Brien, 2001). 
 During the early years of the last century, it became evident that cocaine was 
addicting and producing serious medical complications, especially with the availability of 
cocaine powder for intranasal or intravenous use (Dackis and O’Brien, 2001). 
 Cocaine affects three major dopaminergic systems: the mesolimbic (ventral 
tegmental area to nucleus accumbens), the mesocortical  (VTA to medial prefrontal cortex 
and orbitofrontal cortex), and the nigrostriatal. The main synaptic action of cocaine in the 
reward pathway is to block reuptake of dopamine, norepinephrine, and serotonin, acting 
through cocaine-binding sites on bioamine uptake transporters (Figure 8) (Brust, 2004). 
Recent studies have confirmed an increase of 20% or more in dopamine activity in the 
mesolimbic and mesocortical brain areas in humans that use relevant doses of cocaine. 
There is also evidence that the level of euphoria experienced with cocaine correlates with 
the degree of dopamine change in the corpus striatum (Marc and Schuckit, 2006). 
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Figure 8. The mechanism of action of cocaine (adapted from Moussa et al., 2006). 
5. From pleasure to drug addiction 
One of the main reasons for the consumption of drugs is the pleasure that it 
causes. According to folk psychology, humans tend to repeat behaviors that bring 
pleasure and relieve suffering. Most drugs of abuse act on ancient and remarkably 
conserved neural mechanisms, associated with positive emotions that evolved to mediate 
incentive behavior. Drugs stimulate positive emotions and block bad ones such as: 
anxiety, low mood, emotional suffering and others. However this pleasure tends to 
disappear with the continued use of drugs and bad effects in other systems such as 
memory, mood, reward, learning and behavior begins to appear (Nesse and Berridge, 
1997). 
A study realized with three different groups of ecstasy users: the first is a group of 
regular ecstasy users who had taken MDMA (3,4-methylenedioxymethamphetamine) on 
ten or more occasions; the second is a group of novice ecstasy users who had taken 
MDMA on fewer than ten previous occasions; and the third is a control group who had 
never taken MDMA, shows the disappearance of good feelings (good mood and pleasure) 
with the continued use of ecstasy and the appearance of bad mood and lacks in memory. 
All three groups reported positive mood at the dance club (on-drug). Nevertheless two 
days after, the ecstasy users felt significantly more depressed, abnormal, unsociable, 
unpleasant, and less good tempered, than the controls. The cognitive performance such 
as verbal recall and visual scanning was significantly reduced on regular users. Memory 
recall show also worst results compared to regular users (Parrott and Lasky, 1998).  
This occurs because persistent drug use induced neuroadaptations in molecular, 
cellular and neural system levels that are critical in the transition to addition. These 
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neuroadaptations occur, in the brain, to support the constant presence of drugs and 
decrease the strong stimulant response caused by drug use. In consequence, 
psychological function is also changed. Initially, occurs the decreasing of the pleasure and 
the beginning of the unpleasant withdrawal symptoms (Koob and Moal, 2001; Robinson 
and Berridge, 2003). 
The withdrawals are the symptoms of reversing the development of 
neuroadaptation to a drug. The drug users feel physical discomfort, psychological pain 
and other symptoms that differ according to the drug, and discourage people from trying 
to escape their addiction (Koob and Moal, 2001; Robinson and Berridge, 2003). With the 
continued consumption of drugs, the drug users become drug abusers, as drug induce 
sensitization of brain systems and the users start to have a compulsive behaviour to take 
addictive drugs. Furthermore, drug abusers have dysfunction of frontal cortical systems. 
The frontal cortical system regulates decision making and has an inhibitory control over 
behavior. The presence of drugs leads to impaired judgment and promotes impulsivity in 
addicts (Robinson and Berridge, 2003). 
6. Tolerance and sensitization in drug of abuse 
Tolerance is a decreased sensitivity to a drug that develops as a result of repeated 
exposure to it. In this case the drug has fewer effects following repeated exposures. 
Therefore a higher dose of drug is required to produce the same effect (Figure 9)(Brust, 
2004). Tolerance is an expected accompaniment of regular drug use that reflects the 
adaptation of the receptor site to the presence of the drug. The function of tolerance is to 
maintain homeostatic balance functioning in spite of the stimulating effects of a foreign 
substance (drug abuse). Dopamine and other neurotransmitters are present in the brain at 
higher levels than usual, so the brain tries to adjust, by turning off some of the receptors 
(locks) into which that molecular key fits. The system may also change the level of 
neurotransmitters which it produces in order to compensate for the increased levels of 
whatever drug is being taken. Depending on the drug, these processes can happen in a 
matter of minutes or over several weeks (Miller and Gold, 1991). 
Sensitization or reverse tolerance is an increase in a drug effect that occurs after 
repeated exposures to the drug. In this case the drug has more effects than that before 
exposure it. Therefore a lower dose of drug is required to produce the same effect (Figure 
9) (Swift and Lewis, 2009). This term is well explained with incentive sensitization theory. 
It refers to neurobiological changes that occur in brain mesolimbic dopamine systems and 
other structures that belong to the same brain circuit that mediate the psychological 
function of incentive salience (“wanting”) (Berridge and Robinson, 2011).  
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Figure 9. Shifts in a dose-response curve with tolerance and sensitization. 
Drug abuse causes tolerance in the body of the drug users by many mechanisms. 
One of them is natural or innate tolerance. Natural tolerance occurs when preexist inter-
individual variations in sensitivity to the drug, before the first administration. It can arise 
from genetic variation of receptors at which the drug acts or differences among individuals 
in drug absorption, metabolism, or excretion. Genetic variability is strongly influenced by 
the environment. Innate tolerance is observed with alcohol. People who have low innate 
sensitivity, in young adults are of higher risk for alcoholism later (Golan et al., 2012). 
Whereas innate tolerance has already preexisted in our body, acquired tolerance is 
determined by an individual's experiences that results from exposure to drug abuse. This 
kind of tolerance can develop during a single drug exposure (acute tolerance) or during 
from repeated exposure (chronic tolerance) (Goudie and Young, 1995). 
Pharmacologists divide tolerance into two broad categories: dispositional or 
pharmacokinetic tolerance, which reduce the concentration of a drug or its duration of 
action in a target system; and functional or pharmacodynamic tolerance, which reduce the 
sensitivity of drug-sensitive systems to a given drug concentration (Krasnegor, 1978; 
Goudie and Young, 1995). Dispositional tolerance occurs when the body speeds up the 
metabolism of the drug in order to eliminate it. There is a physiological change in 
absorption, distribution, metabolism, or excretion that diminish the concentration of a drug 
at effectors sites. For example, an increase in the production of enzymes in the liver that 
breaks down the drug (Krasnegor, 1978). Functional tolerance is described for changes in 
sensitivity that results from adaptive changes in drug-sensitive systems that diminish the 
initial effects of a drug. It occurs when the brain learns to compensate for the effects of the 
drug by using parts of the brain that are not affected. This happens in 
chronic alcohol and marijuana users. The brain manages to function quite well despite 
levels of intoxication that would incapacitate people who are less accustomed to the drug. 
Tolerance of psychoactive drugs is largely functional (Krasnegor, 1978). 
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6.1 Alcohol 
Both types of tolerance occur with the consumption of alcohol. Initially occurs the 
pharmacokinetic tolerance and then pharmacodynamic tolerance. The pharmacokinetic 
tolerance is recognizable through a slight increase in both ADH activity and in the liver 
microssomal ethanol-oxidizing system (MEOS). For this reason, the elimination of alcohol 
becomes more rapid in chronic users. Functional tolerance result of a direct adaptation of 
CNS tissues to alcohol, so it is necessary drink more quantity of alcohol for have the same 
effect (Sommer and Spanagel, 2012). 
6.2 Opiates 
Tolerance develops rapidly to most opioids, particularly with the more potent 
analgesics. After repeated uses of opiates, it produces complete tolerance to their 
euphoric effects, as well as sedation and respiratory depression. In chronic users, it 
causes pupils constriction, producing the pinpoint pupils, as well as slow bowel function. 
Because of this differential tolerance to specific opiates effects, long term opiate users 
have little risk of overdose (Dupont, 1997). Cross-tolerance is also common among the 
opioids, with a predictable variability depending on the opioid receptor type most 
prominently affected (Marc and Schuckit, 2006). 
6.3 Cannabis  
 The users of cannabis can develop tolerance, if they consume high doses of 
cannabis for a sustained period of time. The phrase “Less is more” was the slogan used in 
1976 to deter recreational consumption of cannabis: “The less frequently a person users 
cannabis, the less likely is that person to develop tolerance to the original dose, and the 
less likely is that person develop cannabis tolerance”. In fact, little tolerance is observed 
when the doses of cannabis are small, and infrequent for limited duration  (Mathre, 1997). 
6.4 Cocaine 
  Cocaine has optimal conditions to develop tolerance, mainly acute tolerance. Due 
to the short action of cocaine, acute tolerance  develops within 24h (Grabowski, 1994). 
 Cross tolerance occurs when cocaine users consume the drug with other 
psychostimulants as amphetamines and methamphetamines. Repeated administration of 
cocaine induced tolerance to the effects of methamphetamines, and repeated exposure to 
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amphetamines causes tolerance to cocaine. However cross-tolerance is not observed in 
opiates. Repeated administration of morphine did not induce tolerance to cocaine (Higgins 
and Katz, 1998). 
 The main symptoms caused by cocaine tolerance are: progressive increases of 
irritability, restlessness, hyper vigilance, paranoid and suspicious behavior (Grabowski, 
1994).  
7. Addiction and physical dependence in drug of abuse 
Addiction or dependence (described in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) used by the American Psychiatric Association) is defined as a 
chronic relapsing brain disease that is characterized essentially by compulsive drug 
seeking and use, despite negative and dangerous effects. It is considered a brain disease 
because drugs change the brain´s structure and how it works. These brain changes can 
be long lasting and can lead to many harmful, often self-destructive, behaviors (Mc Lellan 
et al., 2000). 
The physical dependence occurs with the chronic use of any substance, legal or 
illegal, even when taken as prescribed. It occurs because the body naturally adapts to 
chronic exposure to a substance, and when that substance is taken away, symptoms can 
emerge while the body readjusts to the loss of the substance (McLellan et al., 2000). This 
adaptation can result in withdrawal symptoms when drugs of abuse are discontinued. That 
means that a person needs a drug to function normally (O´Brien and Volkow, 2006) 
The Diagnostic and Statistical Manual of Mental Disorders uses the term 
"substance use" and “substance dependence” to refer a maladaptive pattern of substance 
use that leads to clinically significant impairment. Drug abuse is associated to some 
symptoms such as: failure to fulfill major role obligations; legal problems; use in situations 
that are physically hazardous; and continued use despite persistent social or interpersonal 
problems. The term dependence includes symptoms as: drug taking in larger amounts 
than intended; inability to cut down on drug use; a great deal of time spent in activities 
necessary to obtain the drug; and continued use despite knowledge of health or social 
problems caused by the drug (McLellan et al., 2000). 
7.1 Alcohol 
Dependence of alcohol or chronic alcoholism is characterized by symptoms similar 
to those found with other forms of drug addiction, but it also presents other typical 
neurological, psychiatric, and physical disorders. Studies demonstrate a possible 
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biochemical link between alcoholism and opiates in inducing their respective 
dependences. The products of alcohol metabolism (ex: isoquinolines) may interact at 
opiate receptor sites, and causes marked alteration in the cerebrospinal fluid (CSF) 
content of proopiocortin-related peptides which may play a role in the alcohol-seeking 
behavior typical of the syndrome (Genazzani et al., 1982). 
7.2 Opiates 
Physical dependence in opiates is explained by inhibition of the functional activity 
of the cAMP pathway, indicated by cellular levels of cAMP and cAMP-dependent protein 
phosphorylation. The cAMP pathway is implicated in neural-specific phenomena, in 
particular, the regulation of synaptic transmission. With continued opiate exposure, 
functional activity of the cAMP pathway gradually recovers to normal, and on addition of 
an opioid receptor antagonist, cAMP levels increase far above control values. These 
changes in the functional \state of the cAMP pathway are mediated via the induction of 
adenylyl cyclase and protein kinase A (PKA) in response to chronic administration of 
opiates. These adaptations in cAMP pathway contribute to opiate dependence, and the 
activation of the cAMP pathway observed on removal of opiates causes withdrawal 
symptoms (Figure 10) (Nestler, 2004). 
 
 
 
Figure 10. The cAMP pathway in opiate dependence (adapted from Nestler, 2004). 
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7.3 Cannabis 
Cannabis dependence is very similar to other substance dependence disorders, 
although it is likely to be less severe. Adults seeking treatment for cannabis abuse or 
dependence average more than 10 years of near-daily use and more than six serious 
attempts at quitting. Most perceive themselves as unable to stop, and most experience a 
withdrawal syndrome upon cessation (Budney et al., 2007).  
The risk of dependence is higher in identical twins of individuals with cannabinol 
dependence than it is for fraternal twin pairs, because there is a genetic predisposition 
toward dependence on cannabinols that influences the CB receptors or cannabinol-
metabolizing enzymes. The symptoms of cannabis dependence is characterized by lack 
of mental drive and focus along with the cognitive impairments that can interfere with job 
or school performance, impair coordination and judgment important for driving, or  
contribute to legal problems (Marc and Schuckit, 2006; Budney et al., 2007). 
7.4 Cocaine 
 Cocaine dependence and addiction is typically associated with frequent and 
intense drug wanting triggered by internal or environmental cues associated with past 
drug use (Kilts et al., 2001). Cocaine causes psychological and physiological problems 
that can be associated with dependence. More than 90% of people who are cocaine 
dependent describe a prominent and disturbing physiological withdrawal syndrome 
involving depression, somnolence, and intense hunger. These symptoms are experienced 
for several days following abstinence. While physiological dependence is characterized by 
an intense craving for cocaine, fatigue and an increase in appetite. The symptoms of 
psychological dependence are usually characterized by a major change in a person’s 
personality.  In cocaine abusers the drug becomes their top priority and they may let other 
activities they have enjoyed in the past take a back seat. The person may also become 
obsessed with making sure to always have enough cocaine (Marc and Schuckit, 2006). 
8. Withdrawal syndrome in drug of abuse 
Withdrawal syndrome results in physical, behavioral as well as motivational 
symptoms following cessation from the continuous use of an addictive drug. The character 
and severity of the symptoms depend upon the particular drug, the daily dose, the 
frequency and the duration of drug use (Koob et al., 1999). 
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While in several psychoactive substances as: barbiturates, alcohol, stimulants, 
opiates and benzodiazepines the withdrawal syndrome can cause severe effects, in other 
psychoactive substances as:  caffeine and nicotine the withdrawal effects are less felt. A 
mild withdrawal is associated with cannabis use, while there is no evidence of withdrawal 
syndrome related to LSD. The changes in mood and in motivation are some symptoms 
caused by withdrawal syndrome There are four withdrawal syndromes, with each 
representing the opposite of the acute effects of the drugs of that class. (U.S. Congress 
Ofice of Tecnology Assessment, 1993), as explained below. 
The depressant withdrawal felt in alcohol, barbiturates or benzodiazepines 
abusers consist in signs and symptoms such as: anxiety, insomnia, seizures, delirium 
(more precisely delirium tremens, typically in alcohol withdrawal syndrome), nausea, as 
well as higher blood pressure and heart rate. (Lowinson et al., 2005). 
The main symptoms associated with opiate withdrawal are: discomfort as 
psychological as physical, dilatation of pupils, stuffy nose and gooseflesh. Although these 
symptoms are extremely uncomfortable, they are rarely life threatening (Dupont, 1997). 
The stimulant withdrawal syndrome felt by cocaine, amphetamine and ecstasy 
abusers consists basely of sleeping too much, eating too much, and depression. When 
there is a combination of two different types of drug such as: alcohol and cocaine or 
heroin and cocaine, the stimulant portion of the withdrawal is treated with education and 
reassurance, while the depressant and opioid withdrawal is likely to require short-term 
medications (Marc and Schuckit, 2006). 
The withdrawal syndrome felt in cannabinoids and hallucinogens abusers are 
less clinically relevant (U.S. Congress Ofice of Tecnology Assessment, 1993) 
8.1 Alcohol  
Alcohol withdrawal syndrome (AWS) can be a life threatening condition, which may 
occur following abrupt cessation of alcohol intake in individuals whose consumption has 
been extensive and excessive (Cooper and Vernon, 2012). This syndrome is 
characterized by a variety of symptoms that depends on the frequency and severity. It is 
typically related with the amount and duration of alcohol use. Depending on the range of 
severity, this kind of users narrows essential elements of withdrawal syndrome that might 
include: drink seeking behaviour; an increase tolerance to alcohol; repeat withdrawal 
symptoms; repeat relief or avoidance of withdrawal symptoms by further drinking; 
subjective awareness of a compulsion to drink; replacement of the syndrome after 
abstinence (Edwards and Gross, 1976). 
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Although there are many exceptions, the withdrawal syndrome appears 6 to 12 
hours after the last alcoholic drink, in individuals that are used to drink about 200-300 g of 
alcohol a day for several years. This syndrome cannot occur without a high degree of 
CNS tolerance, but tolerance can exist without clinically manifest withdrawal symptoms. At 
first, the symptoms are intermittent and mild, causing a little incapacity and one may be 
experienced without others. With the increase of the dependence, the frequency and the 
severity of the symptoms are also increased and the patient has severe multiple 
symptoms every morning on waking (Marc and Schuckit, 2006). 
The spectrum of symptoms is ample and includes: tremor, anxiety, insomnia, 
nausea, sweating, headaches, tinnitus, itching, muscle cramps, palpitations, mood and 
gastrointestinal disturbance. After that, the patients could develop further complications 
such as: perceptual distortion, hallucination and grand-mal seizures. The most life-
threatening manifestation of AWS is delirium tremens, which affects approximately 5% of 
alcohol abusers. This symptom occurs within 2–4 days after alcohol cessation. The 
associated mortality rate of delirium tremens is 1–5% and the condition may result in 
respiratory and cardiovascular collapse (Marc and Schuckit, 2006; Cooper and Vernon, 
2012). 
8.2 Opiates 
Opiate withdrawal refers to the wide range of symptoms that occur after stopping 
or dramatically reducing opiate drugs after heavy and prolonged use. One of the reasons 
commonly given by opiate users for continuing opiate use is the avoidance of withdrawal 
symptoms. They begin a few hours from the last dose, the peak appears after two to three 
days, and start to subside after a week. In opiod abusers some withdrawal symptoms will 
occur several times per day and during the life of a patient before they seek treatment 
(Gerada and Ashworth, 1997; O’Brien et al., 1998). 
The heroin withdrawal causes many symptoms such as: craving, nausea, 
anorexia, anxiety and restlessness, aching bones and muscles, insomnia or yen sleep, 
and hot and cold flashes. Therefore there are signs considered comprised such as: 
tremors, yawning (addiction and dependence), vomiting, diarrhea, perspiration, 
lacrimination, rhinorrhea, increased respiration rate and depth, goose flesh, mydriasis 
(dilated pupils), spontaneous orgasm, increased temperature, tachycardia, and increased 
blood pressure (Gallimberti et al., 1993). 
The treatment for opiate withdrawal consists in giving drugs that modify the 
neurotransmitter system responsible for the behavioural and biochemical opioid 
withdrawal effects. The usual treatment for opiate withdrawal is replacement with clonidine 
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or another adrenergic agent. Recently this medication was substituted by buprenorphine, 
a partial opioid agonist used for the treatment of opioid withdrawal (Kosten and O’Connor, 
2003). 
8.3 Cannabis 
Upon abrupt cessation of high doses of marijuana (cannabis) administration, we 
can observe withdrawal syndrome (Marc and Schuckit, 2006). It syndrome is 
characterized by many symptoms as: yawning, anger/aggression, irritability, anxiety, 
decreased appetite/weight loss, restlessness and sleep difficulty. Other signs have also 
been reported, but with less frequently such as: depressed mood, stomach pain/physical 
discomfort, shakiness, and sweating (Vandrey et al., 2005; Budney et al., 2007). 
Most symptoms beginning within 24 h of abstinence, peak between day two and 
six of abstinence and most return to baseline by day 14. Other symptoms as: sleep 
difficulty, anger/aggression, irritability and physical tension have persisted for three to four 
days. Strange dreams failed to return to baseline during the 45-day abstinence  (Winstock 
et al., 2009). 
 The cannabis withdrawal syndrome acts as a negative reinforcement for relapse to 
cannabis use in individuals trying to abstain. Hence there is a pharmacological treatment 
aimed at alleviating cannabis withdrawal might prevent relapse and reduce dependence. 
This medication works as CB receptor agonists that directly suppress the withdrawal 
syndrome and alleviate symptoms of cannabis withdrawal such as dysphonic mood and 
irritability (Weinstein and Gorelick, 2011).  
8.4 Cocaine 
After cessation or reduction in prolonged, heavy use of cocaine, the presence of 
withdrawal syndrome appears. The symptoms described for cocaine withdrawal does not 
result in the peripheral signs and symptoms of autonomic instability often seen in other 
drug withdrawal syndromes. Cocaine withdrawal is mainly associated with significant 
psychiatric symptoms such as: dysphoria, anhedonia, anergia, anxiety, irritability, 
boredom, craving (Kampman et al., 2000). Nevertheless, there are other symptoms 
associated with cocaine withdrawal such as: appetite disturbance, gastrointestinal upset, 
depression, muscle pain, and tremor (Brower et al., 1988).The symptoms begin within 24h 
of stopping cocaine, and become most intense for 3–5 days. These symptoms remain at 
decreasing intensity for many weeks, and perhaps months after cessation of cocaine use 
(Brower et al., 1988; Marc and Schuckit, 2006). 
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Cocaine withdrawal is also characterized by electroencephalogram (EEG) 
changes, usually involving an excess of alpha power along with a decrease in the faster 
delta and theta frequency bands, with at least one report of a continuation of these 
findings in some individuals for 6 months. This phenomenon is related to changes in 
dopamine (DA) transmission, in several brain areas, including the amygdala. Additional 
changes are also observed in cerebral glucose utilization and changes in the normal 
hormonal alterations, including prolactin (Alper, 1999). 
9. Toxic reactions and overdose in drug of abuse  
Toxic reactions caused by psychoactive substances consist in toxic physiological, 
psychological, behavioral manifestations and life-threatening reactions resulting from 
intentional and unintentional (accidental) overdose. A drug overdose is the use of drug in 
an amount that is higher than is normally used, or when the drug is taken in combination 
with other drugs inclusive alcohol (Khantzian and McKenna, 1979). 
 All drugs have the potential to produce toxic effects and cause overdose by a 
variety of mechanisms such as: Toxic effects that are direct and predictable following a 
drug overdose occur due to the drug itself or it may reflect a change in the metabolism of 
the drug, resulting in a toxic metabolite; Toxic effects may be direct and predictable 
following repeated dosing of the drug, are mediated by metabolites, pharmacologic in 
nature or immunologic in mechanism; Toxic effects may be direct and unpredictable, 
either following one dose or just a few doses occur due to a idiosyncratic response to 
drugs and may be immunologic or pharmacologic in mechanism. This type of toxic effects 
appear in only a very few patients and have no good predictors for their occurrence; The 
last one are toxic effects that results of some drug interaction or may be caused by a 
change of tolerance due to temporary drug abstinence (Khantzian and McKenna, 1979; 
Kjelsberg et al., 1995).  
With the exception of using opioid antagonists, overdose conditions are usually 
treated by supporting the vital signs, so that the body can metabolize and excrete the 
drugs and return to normal. After that is necessary to control of symptoms regardless of 
the specific drug involved. If the drugs involved in overdose were depressants, the patient 
will require control of respirations and bolstering of blood pressure, because the vital 
signals were depressed. If the drugs involved in overdose were stimulants or opioids, the 
emergency treatment depends upon the vital sign changes. The mainly treatment in these 
cases includes a controlling high blood pressure and elevated body temperature. If the 
drug involved was opioid, the clinical should administer an opioid antagonist (e.g., 
naloxone). Another general rule is to consider gastric lavage, followed by the possible use 
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of activated charcoal if there is evidence of recent oral administration of the drugs (Marc 
and Schuckit, 2006). 
9.1 Alcohol 
An overdose of alcohol occurs when a person has a blood alcohol concentration 
(BAC) sufficient to produce impairments that increase the risk of harm. The severity of 
toxic reaction could vary among individual characteristics such as: age, drinking 
experience, gender and the amount of drinker food eaten (Li et al., 2003). 
There are two forms of ethanol intoxication: pathological intoxication, also called 
idiosyncratic intoxication and acute alcoholic paranoid state. The acute alcoholic paranoid 
intoxication consists of sudden extreme excitement, sometimes with delusions, 
hallucinations, and violent behavior, even homicide. In some cases after minutes to hours, 
there is amnesia for the episode. The pathological intoxication is characterized by 
psychological dissociative reactions resulting of paradoxical excitation (Brust, 2004). 
Acute overdose with ethanol presents primarily as CNS depression. The most 
common symptoms of acute alcoholic overdose are: signs of vasodilatation (flushing, 
tachycardia, hypotension, and hypothermia), depressed consciousness, hyponatremia, 
hypovolemia, electrolyte imbalance, hypoglycemia and abnormal temperature. In chronic 
ethanol intoxication is common to appear hepatotoxicity and cardiotoxicity, causing 
potential cirrhosis and cardiomypathy progressing to failure, respectively (Malcolm and 
Alkana, 1983; Brust, 2004; Waring et al., 2008). 
The treatment of severe ethanol poisoning is similar to that of other depressant 
drugs. Death is from respiratory depression, and so patients require artificial ventilation in 
an intensive care unit. In chronic ethanol ingestion is necessary to make the detoxification 
with employ of chlordiazepoxide, to prevent delerium tremens and other signs of ethanol 
withdrawal  (Brust, 2004). 
9.2 Opiates 
The opioid overdose is usually an acute, life-threatening event that is most often 
accidental but that could represent a deliberate suicide. At least one overdose occurs 
during the course of 50% of heroin users. The user is likely to be found in a semi-
comatose condition with evidence of a recent intravenous injection. The risk of overdose 
depends on many factors such as: the high-quality heroin (increase the risk) or use of a 
more potent opioid (e.g. fentanyl), the price of the drug (less cost, high risk of overdose), 
the use of quinine for dilute the drug can decrease the activity of the cardiac pacemaker, 
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decrease cardiac electrical conductivity, and thereby induce a prolonged cardiac electrical 
refractory period that increases the risk for ventricular fibrillation (Marc and Schuckit, 
2006). 
Acute overdose causes depression, especially of the respiratory centre. The 
symptoms associated with opioids overdose include: reduced levels of consciousness, 
lethargy, miosis (pinpoint pupils), flaccid muscle tone, cool skin, hypotension, bradycardia, 
hypothermia, cyanosis, hypoventilation, apnea and coma. Death is usually due to 
respiratory failure (Darke and Zador, 1996). 
Opioid overdose is treated by administration of opioid antagonist such as naloxone 
or naltrexone. Naloxone is mainly used in the treatment of opioid-overdose-induced 
respiratory depression, in ultra-rapid detoxification and in combination with buprenorphine 
for maintenance therapy to prevent intravenous abuse. However the administration of 
naloxone in opioid-dependent patient has some implications that include: the occurrence 
of vomiting and aspiration is potentially life threatening, and in patients treated for severe 
pain with high-dose naloxone may cause catecholamine release and consequently 
pulmonary edema and cardiac arrhythmias. So the administration of naloxone imply an 
adequate monitoring of the cardiorespiratory status of the patient (Dorp et al., 2007). 
9.3 Cannabis 
Cannabis has acute and chronic effects on mental health. Acute effects vary 
among individuals and the degree and severity of these effects is related to the dosage, 
method of administration, environment and personality of the user. Chronic effects could 
cause serious psychiatric illness such as: depression, anxiety, low motivation, psychosis 
and schizophrenia (Cho et al., 2005). 
Although cannabis cause less clinically relevant effects, when used in higher 
quantities causes adverse toxic reactions. High doses of cannabis cause auditory and 
visual illusions or hallucinations that consist of flashes of light or color, geometric figures, 
human faces, or complex pictures. Also, it can cause bizarre illusions include loss of depth 
perception, the appearance of people talking with their mouths, voices unsynchronized, 
and “streaking” (moving light sources in a dark environment becoming long streaks as in a 
time-exposed photograph).The patients can describe fantastic complex hallucinations with 
extraordinary dilation of subjective time, and there are some reports that propose that 
marijuana improves night vision. If increasing more the higher doses of cannabis, we 
could observe confusion, disorientation, anxiety, psychotic depression or excitement, 
bradycardia and hypotension occur. Nowadays, fatal overdose has not been documented 
(Hollister, 1986; Brust, 2004; Cho et al., 2005; Calafat et al., 2012). 
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Cannabis severe symptoms are treated by administration of benzodiazepines, 
haloperidol or other anxiolytic. This medication is adequate for treatment of anxiety and 
feature of cannabis withdrawal (Piomelli, 2004). 
9.4 Cocaine  
Overdose of cocaine occurs in users with the following characteristics: female 
gender, injectors of cocaine, to have a longer cocaine use careers, to have used more 
cocaine in the preceding month and preceding 6 months, to have higher levels of cocaine 
dependence and more extensive polydrug use (Kaye and Darke, 2004). 
Cocaine acts in CNS and in cardiovascular system cause biphasic response. In 
lower doses it tends to improve motor performance and to produce a decrease in heart 
rate via actions on the vagus nerve. In high doses it causes deterioration in CNS, with 
subsequent severe tremors and possible convulsions, and in cardiovascular system 
causes an increased heart rate and vasoconstriction, with a resulting elevation in blood 
pressure (Marc and Schuckit, 2006). The most common symptoms of overdose are: 
palpitations, nausea, vomiting, dilated pupils, an increased body temperature, intense 
sweating, seizures, muscle contractions, arrhythmias due to catecholamine release. Fatal 
cocaine overdose has also occurred due to brain hemorrhage, stroke and kidney failure, 
myocardial infarction, hyperthermia, or ventricular arrhythmias (Gerada and Ashworth, 
1997; Kaye and Darke, 2004). 
The time course of effects differs with the route of administration. Intravenous use 
of cocaine has an onset of about 3–5 min, with peak effects at 10–20 min, and a fading 
high by 45 min or less. The risk of overdosing increases  when it is administered in a way 
that causes a rapid increase in brain levels of the drug, as happens with injected cocaine 
(Kaye and Darke, 2004; Marc and Schuckit, 2006). 
Actually there is no specific antidote for cocaine overdose. The treatment options 
are supportive and symptomatic in nature, and will depend on which clinical features are 
present. If the patient is unconscious should be ensured the adequate ventilation and 
volume depletion, cardiac arrhythmias, seizures, hypertension, agitation, and 
hyperthermia should be managed symptomatically. Benzodiazepines are the medication 
of choice for the management of patients with agitation, seizures, tachycardia, and 
hypertension. If hypertension persists after the administration of benzodiazepines specific 
antihypertensive therapy (e.g. intravenous nitrates or calcium-channel blockers) can be 
given. Beta-blockers should be avoided due to the risk of coronary vasoconstriction and 
paradoxical hypertension. However, has been described recently, that the administration 
of intravenous lipid is an effective treatment for cardiovascular complications associated 
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with local anaesthetic-induced toxicity. This medication is also acts as an effective 
antidote to the overdose of lipid-soluble drugs including beta-receptor antagonists, 
calcium channel blockers and antidepressants (Carrera et al., 2005; Jakkala-Saibaba et 
al., 2011). 
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1. Objectives of the thesis 
The general objective of this work was to evaluate through surveys and 
collection/analysis of biological samples, the drug abuse patterns in Coimbra recreational 
nightlife. 
The specific objectives of this work were: 
 
- To investigate the presence of psychoactive substances in biological samples 
ceded by willing participants of this study; 
- To analyze qualitatively and quantitatively the components of these samples by 
GC-MS, to be implemented in the present studies; 
- To confront the answers in the surveys with the chemical results of analyzed 
samples; 
- The final objective is to contribute for a better risk management concerning drug 
abuse among young people, by comparing their perception of the risk abuse 
patterns. 
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1. Surveys 
1.1 Characterization of the study 
 This study is observational, descriptive and cross-sectional. Studies with these 
characteristics allow describing a phenomenon or a concept related to a specific 
population. This type of study is used to determine the characteristics of a population or a 
sample. It is also used to assess the prevalence of conditions in a population, since the 
exposure is measured at the same point in time (Fortin, 1999). 
1.2 Study population 
 The study population comprehends all young adults between 18 to 30 years who 
attend recreational nightlife, in Coimbra, at least once per week. 
1.3 Study sample 
 To determine the sample of this study, it was decided to use the non-randomized 
process of accidental sampling. Although this type of process does not ensure that all 
elements of the population have the same probability of being included in this sample, it 
facilitates the inclusion of a higher sample size. The data were collected in days of higher 
affluence, in recreational spaces, from May to September 2013. For this study the 
inclusion criteria was: to be aged between 18-30 years old and to be in a recreational 
context at nights of data collection. No exclusion criteria were used for this study. 
1.4 Legal and administrative procedures 
  Approval by National Commission of Data Protection. 
 Approval by ethical commission of Faculty of Pharmacy, and University of Porto. 
 Approval by City Hall of Coimbra. 
 Approval by ARS-IP. 
 Written informed consent by all participants. 
 
1.5 Study variables 
In this work it was used, as research tool, a survey validated for Portuguese population. 
This survey is composed for five sections, which allow defining the following variables: 
 
 Socio-demographic characteristics: age; gender; student/non-student; typology of 
degree; course; residence; type of study; professional status and number of household. 
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 Recreational nightlife habits: frequency of nights out per week and per month; number 
of recreational spaces frequented per night; money spent per night. 
 
 Health information: weight; height; health problems; use of medications with or without 
prescription; last food intake (in number of hours ago). 
 
  Problems due to use of psychoactive substances: health problems related with the 
use of psychoactive substances; influence of psychoactive substances in friendship 
relations; driving under psychoactive substances; problems with authority; perception of 
risk. 
 
  Drug abuse patterns: type of psychoactive substances used during the last week; 
dosage; route of administration; type of psychoactive substances used in the end of the 
night. 
1.6 Collection of surveys  
  The surveys were made in days of higher affluence towards the door of nightclubs 
or inside it, as previously agreed with public relations of clubs and pubs in Coimbra. The 
young adults between 18 to 30 years, who were in nightclubs, were freely invited to 
participate in this study. After written informed consent, the surveys and biological 
samples were collected and transported to the Department of Toxicology, Faculty of 
Pharmacy, University of Porto. All surveys and written informed consent remain stored in 
a biobanc of this University for at least five years. After this period of time it can be 
automatically destroyed. All participants that wanted to be informed about the results of 
toxicological analysis were sent an e-mail with the respective results. 
1.7 Statistic treatment  
 All information collected through the surveys were quantitatively analyzed, using 
the Software Package for Social Sciences (SPSS®), version 17.0 for Microsoft 
Windows®. For descriptive analyze of the data, was determined the counts and the 
frequencies of the nominal variables. For numeric variables, it was used the measures of 
central tendency (mean, mode and median), the dispersion (standard deviation) and the 
amplitude variation (minimum and maximum). 
 Due the short size of the sample, for comparative and inferential analyze, non-
parametric tests were used: Mann-Whitney test to compare two independent groups ; 
Kruskal-Wallis test to compare two or more independent groups. The Pearson Chi-Square 
test was used with the objective of correlating two independent groups and, when 
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applicable, the Odd’s Ratio. For inferential analysis, it was defined a significance level of 
0,05. 
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1. Identification and quantification of psychoactive drugs in biological samples  
1.1 Ethics statement 
This research was approved by the following institutions: National Commission of 
Data Protection, Ethics Commission of Faculty of Pharmacy University of Porto, City Hall 
of Coimbra and ARS-IP. A written informed consent was signed by all participants of this 
study. 
1.2 Reagents and standards 
All the chemicals used for the ethanol quantification were of analytical grade: 
ethanol (> 99.9%, Panreac, Barcelona, Spain), 1-propanol (> 99%, Sigma-Aldrich Co., St. 
Louis,MO), Triton X-100 (Sigma-Aldrich Co.). 
The analytical standard 9-Tetrahydrocannabinol, molecular mass 314.45 g mol-1 
and the internal standard benzophenone, molecular mass 182.22 g mol−1 were obtained 
from Sigma-Aldrich (St Louis, MO, USA). Methanol and N,O-
bis(trimethylsilyl)trifluoroacetamide/trimethylchlorosilane (BSTFA+1%TMCS) were 
purchased from Sigma-Aldrich (St Louis, MO, USA). Hexane, acetonitrile and ethyl 
acetate were purchased from Merck (Darmstadt, Germany). Potassium dihydrogen 
phosphate and di-potassium hydrogen phosphate were purchased from Merck 
(Darmstadt, Germany). Nitrogen (99.99% purity) and helium (99.99%) were obtained from 
Gasin (Portugal).   
The analytical standard cocaine hydrocloride, molecular mass 339.81 g mol-1 and 
the internal standard benzophenone, molecular mass 182.22 g mol−1 were obtained from 
Sigma-Aldrich (St Louis, MO, USA). 
The cocaine screening test was obtained from commercial brand First Check@ 
Test. 
-  All the reagents used were of analytical grade or from the highest available grade. 
1.3 Biological specimens 
 Blood and oral fluid samples were collected from young adults attending 
recreational nightlife, in Coimbra, at least, once per week. Blood samples were collected 
from the median cubital vein. The collection method used in this study was through a 
commercial vacuum-sampling system, decreasing the risk of contamination. Initially, a 
tourniquet was used to distend the vein prior to sampling. After that, the skin was cleaned 
with disinfectant swabs containing alcohol. In view of the requirement to prevent stress on 
patients, only 5 to 10 mL of blood was collected. These samples were kept in heparin 
tubes at 7ºC. The oral fluid samples were collected through a spitting method (around 1-2 
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mL) for an appropriate collection container and were kept at 7ºC. After the collection, all 
samples were stored and transported, in refrigerator containers, to the Laboratory of 
Toxicology, Faculty of Pharmacy University of Porto. For validation of the analytical 
method for THC, drug-free blood was used, to which was added the appropriate volume of 
THC standards. All samples were stored at -20 ºC prior to analysis. 
1.4 Analysis of ethanol in blood and oral fluid samples 
Sixty nine blood samples, 17 oral fluid samples, and 46 exhaled air samples were 
obtained from these participants. Blood and oral fluid analysis were performed according 
to a previously published method (Pontes et al., 2009).  
1.4.1 Preparation of stock solution 
A sock solution containing ethanol was prepared in commercial deionized water 
from the purchased sample (> 99.9%, Panreac, Barcelona, Spain), at the concentration of 
12g/L. 
1.4.2 Preparation of calibration standard solution 
For blood sample analysis, calibration standard solutions of 0; 0.15; 0.30; 0.60; 
1.20; 2.40 g/L were freshly prepared for each analysis from the stock solution of 12g/L 
ethanol, by adding the appropriate volume to drug-free blood. 
For oral fluid sample analysis, calibration standard solutions of 0; 0.0375; 0.075; 
0.30; 0.60 g/L were freshly prepared for each analysis from the stock solution of ethanol 
12g/L by adding the appropriate volume to drug-free oral fluid. 
1.4.3  Preparation of internal standard (IS) 
 A working solution of 1-propanol was prepared in deionized water from the 
purchased solution of 1-propanol (> 99%, Sigma-Aldrich Co., St. Louis,MO), at the 
concentration of 2,2 g/L. This solution was used as internal standard (IS). 
-  All working and stock solutions were prepared fresh daily and stored at 7 ºC prior use. 
1.4.4  Sample preparation for gas-chromatography flame ionization detector 
1.4.4.1 Drug-free samples 
One drug free blood and oral fluid samples were tested with the same protocol of 
ethanol blood/oral fluid samples respectively, in order to verify the selectivity of the 
method.  
1.4.4.2 Blood samples 
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Two hundred microliters of blood samples were mixed with 40 μL of IS. The 
samples were diluted to 780 μL with the Triton X-100 solution. All samples were vortex 
mixed and centrifuged at 13.000 rpm for 3 min. 0.5 μL of the supernatant were directly 
injected into the GC-FID system. 
1.4.4.3 Oral fluid samples 
Two hundred microliters of oral fluid samples were mixed with 40 μL of IS. The 
samples were diluted to 780 μL with the Triton X-100 solution. All samples were vortex 
mixed and centrifuged at 13.000 rpm for 3 min. 0.5 μL of the supernatant were directly 
injected into the GC-FID system. 
1.4.5 Gas-chromatography flame ionization detector conditions  
The GC used was a ThermoFinnigan Model Focus GC equipped with a FID. The 
injection port of the chromatograph was installed with a glass liner (5-mmi.d.) appropriated 
for split analysis, to prevent the contamination of the GC column with non-volatile material 
from the tested matrices. For blood and oral fluid samples, the liner was replaced after 50 
injections. The analyses were performed under the following chromatographic conditions: 
Column, CPWax 57 CB (WCOT Fused Silica), 25 m × 0.25 mm i.d., DF = 0.2 μm, from 
Varian (Palo Alto, CA). The temperature of the FID was 220ºC, and the injector 
temperature was 220°C. The oven temperature was programmed to 40°C (for 5 min), 
followed by an increase of 10ºC/min until 150ºC. After that, the oven temperature increase 
of 2ºC/min until 210ºC. The carrier gas was helium with a flow of 1.5 mL/min. The injection 
of blood and oral fluid samples were performed by means of a 10 μL Hamilton syringe 
(Model 701 RN) with a removable needle (needle gauge 22S), cleaned under vacuum 
between each injection with the Triton X-100 solution. The volume of injection was 0.5 μL, 
with a ratio of 1:180 min corresponding to a split flow of 120 mL/min for blood and oral 
fluid samples. 
 The representative chromatogram was reprocessed using the following retention 
times for each analyte, presented in Table 1.  
 
Table 1. Retention times of ethanol, and IS analyzed by GC-FID. 
 
Analytes Retention time (minutes) 
Ethanol 3.1 
IS 5.2 
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1.5 Analysis of 9-THC in blood and oral fluid samples 
1.5.1  Preparation of stock solution 
A 1mg/mL methanolic solution containing 9-THC was prepared from the 
purchased solution of 9-THC Sigma-Aldrich (St Louis, MO, USA). 
1.5.2 Preparation of working solutions 
Four working solutions of 10; 100; 1000; 10000 ng/mL were prepared from the 
stock solution (1mg/mL) in methanol. 
1.5.3 Preparation of calibration standard solution 
Calibration standard solutions of 0, 1, 5, 10, 25, 50, 100, 500, 1000 ng/mL were 
freshly prepared for each analysis from working solutions by adding the appropriate 
volume to drug-free blood. 
1.5.4 Preparation of internal standard (IS) 
A working solution of benzophenone was prepared in acetonitrile from the 
purchased solution of benzophenone Sigma-Aldrich (St Louis, MO, USA), at the 
concentration of 40ug/mL. This solution was used as internal standard (IS). 
 
- All working and stock solutions were prepared fresh daily and stored at -20 ºC prior 
use. 
1.5.5  Sample preparation for gas-chromatography mass spectrometry 
1.5.5.1 THC extraction from biological samples 
 Different methods of LLE and SPE were tested to determine the optimal conditions 
of extraction. The method described is the one that resulted in higher recoveries. Hence, 
liquid-liquid extraction (LLE) was performed in falcon tubes of 15 mL. To each falcon 1 mL 
of blood sample and 50μL of I.S were added. All tubes were vortex mixed and added 1 mL 
of phosphate buffer (pH 4.1 M). The tubes were vortex mixed again and 5 mL of 
hexane/ethyl acetate (5/1) were added subsequently. The tubes were shaken on a rotary 
mixer for 10 min and centrifuged at 2500 rpm for 20 min. The organic layer was 
transferred to GC vials. A second aliquot of 5 mL hexane/ethyl acetate (5/1) was added to 
the remaining aqueous layer and the process was repeated to maximize recovery. The 
solvent extracts were totally evaporated under N2 at 50 ºC. 
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1.5.5.2 Derivatization procedure  
 In this study, THC was derivatized by silylation, reacting with BSTFA and 1% 
TMCS. BSTFA is the silylation reagent that reacts with 9-THC replacing active hydrogens 
by a –Si(CH3)3 (trimethylsilyl) group. TMCS increases the reactivity of BSTFA. 9-THC 
measurement was performed with the addition of 60 μL of BSTFA +1%TMC. The samples 
were vortex mixed and heated for 60 min at 70 ºC. After cooling to room temperature, the 
samples were injected into the GC-MS system. 
1.5.6 Gas-chromatography mass spectrometry conditions  
 Quantitative GC-MS analysis was performed on a Varian CP-3800 gas 
chromatograph (USA) equipped with an ion-trap Varian GC-MS Saturn 4000 mass 
detector. Chromatographic separation was achieved using a capillary column VF-5ms (30 
m × 0.25 mm i.d. × 0.25 μm) and a high-purity helium C-60 carrier gas. An initial 
temperature of 100 ºC was maintained for 1 min, increased to 300 at 15 ºC/min, and held 
for 1 min, giving a total run time of 24.33 min approximately. The flow of the carrier gas 
was maintained at 1.0 mL/min. The injector port was set at 250 ºC. Analyses were 
performed in full scan in splitless injection mode.  
The obtained full scan chromatogram was reprocessed using the following 
selected qualifier ions and retention times for each analyte, presented in Table 2. The 
underlined ions were used for quantification. 
 
Table 2. Retention times and m/z ions of 9-THC and IS by GC-MS. 
 
Analytes Retention time (minutes) Fragments (m/z) 
9-THC 12.32 315; 371;386 
IS 7.76  105; 182 
 
The integration of the chromatographic peaks for quantitative analysis was performed by 
monitoring the fullscan chromatogram with specific selected m/z ions allowing more 
precise peak integration. 
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1.6 Method validation of 9-THC 
 Selective and sensitive analytical methods for the quantitative evaluation of 
psychoactive substances and their metabolites are critical for a successful conduction of 
analytical studies. Bioanalytical method validation includes all of the procedures that 
demonstrate that a particular method used for quantitative measurement of analytes in a 
given biological matrix such as blood, plasma and oral fluid is reliable and reproducible for 
the intended use. The Food and Drug Administration guidance, that is actually accepted 
by the biopharmaceutical industries as the gold standard method validation approach, 
established the fundamental parameters for method validation that include: accuracy, 
precision, selectivity, sensitivity, reproducibility, and stability (Department of Health and 
Human Services, 2001). 
 In this work, the validation methods of 9-THC for blood samples were based on 
the determination of selectivity, linearity, LOD, LLOQ, precision, accuracy, recovery and 
reproducibility. In order to obtain these validation data, calibration curves were prepared 
by spiking blank whole blood with appropriate concentrations of 9-THC standard. 
1.6.1 Selectivity 
Six blank samples with no analytes or IS added were extracted by LLE as 
described previously and analyzed by GC-MS to detect possible chromatographic 
interferences with THC. Chromatographic selectivity was evaluated by the presence or 
absence of co-eluting peaks at the retention times of the analytes. Three independent 
experiments were performed. 
1.6.2 Linearity 
The method linearity was determined by evaluation of the regression curve (ratio of 
analyte peak area and IS peak area versus analyte concentration) and expressed by the 
determination coefficient (r2) using spiked samples. The calibration curve (y = mx + b) 
was obtained using nine different concentrations (0, 1, 5, 10, 25, 50, 100, 500, 1000 
ng/mL). The mean slopes were obtained for calculating the concentration of real samples 
(unknown concentrations). These concentrations were prepared daily as mentioned 
before. 
1.6.3 Limit of detection and lower limit of quantification 
In this work, LOD and LLOQ were obtained based on the standard deviation of the 
response and the slope of the calibration curve. The LOD and LLOQ are expressed 
accordingly to the following equations respectively. The σ is the standard deviation of the 
response and S is the slope of the calibration curve. 
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1.6.4 Precision  
The precision of an analytical procedure is defined as the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions (Department of Health and Human 
Services, 2001). It is expressed as the coefficient of variation (%CV). Intraday precision 
data was quantified by analyzing the areas of three replicates of three concentrations 
(low, 10; medium, 100; and high, 1000 ng/mL) and calculating the %CV. The areas of the 
same three concentrations, injected on three consecutive days, were used to calculate the 
interday repeatability (%CV). A %CV value of ≤15% for interday and intraday analysis was 
considered satisfactory.  
1.6.5 Accuracy 
The accuracy of an analytical method as the closeness of agreement between the 
conventional true value and the value found. It is expressed as a percentage. In this work, 
the accuracy of the THC method was determined by spiking blank matrix with three 
different THC concentrations (low, 10; medium, 100; and high, 1000 ng/mL) and through 
the calculation of the percentage deviation between the calculated value and the nominal 
value [accuracy (%) = (experimental concentration/theoretical concentration) × 100]. A 
deviation percentage of ≤15% was considered satisfactory. 
1.6.6 Recovery 
The recovery was determined by analyzing two sample groups of the same 
concentrations (10, 100 and 1000 ng/mL) in triplicate. In the first group, THC and the 
internal standard were added before the liquid-liquid extraction as following mentioned 
above. In the second group, THC and internal standard were added after the liquid-liquid 
extraction, before drying. The recovery was evaluated by the comparison of the mean 
response of the two groups. The response of the unextracted group represents 100% 
recovery. A deviation percentage of ≤20% was considered satisfactory. 
1.6.7 Reproducibility  
The reproducibility of an analytical method is determined by analyzing the same 
concentration of the sample five times. The objective of reproducibility is to verify that the 
same method will provide the same result. In this work, the reproducibility was determined 
by analyzing the same concentration (100ng/mL) five times. 
52 
 
1.7 Analysis of amphetamines 
 For detection of amphetamines in blood samples, it was used a preliminary test. 
This method consists in identifying the presence of the most known amphetamines as: 
MDMA, MDA and methamphetamines in blood samples, using a GC-MS program called 
NIST (national institute of standards and technology). This program has the majority of the 
standards of psychoactive substances. Knowing the time retention and the ions 
characteristics of each amphetamine, is possible to identify those in your sample 
chromatograms, compared with this data base. 
1.7.1 Sample preparation for gas-chromatography mass spectrometry 
To each eppendorf 1 mL of blood sample and 500μL of methanol were added. All 
tubes were vortex mixed and centrifuged at 13000 rpm for 20 min. The organic layer was 
transferred to new eppendorf and it was reposed for 30min. After the compounds that 
were in solution have precipitated, the sample was centrifuged again at 13.000 for 30 min. 
This procedure was repeated 3 times for all compounds presents in blood samples being 
totally removed. After that, the samples were injected into the GC-MS system. 
1.8 Analysis of cocaine 
 For detection of cocaine in blood samples, it was used a commercial First Check@ 
test. This is a screening test that allow detect cocaine presents in biological samples. 
1.8.1 Sample preparation  
To each eppendorf 150 mL of blood sample and 50μL of HClO4 (20%) were 
added. All tubes were vortex mixed and centrifuged at 13000 rpm for 10 min. 100μL of the 
supernatant was transferred to new eppendorf and 33,3 μL K2CO3 (1.52 M) was added to 
neutralize the pH. The samples were vortex mixed and centrifuged at 13.000 for 1 min. 
100μL of the supernatant was added to the screening test. A positive control sample with 
(10μg/mL) of cocaine standard was prepared in the same conditions. 100μL of this 
solution was also added to the screening test. If the blood samples contain cocaine 
metabolites, will appear one line: the line control. 
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1. Surveys 
1.1 Socio-demographic characteristics  
 In this study participated 78 willingly young adults who were in nightclubs. Most 
of the contacted persons agreed with data collection, but were fearful to provide a blood 
sample. Those 78 engaged, 73,08% of participants were male and 26,92% were female 
(Figure 11), with the range of ages between 18 and  30 years, being the average ages 
22,18 years (Table 3).  
 The majority of the participants were students 75,64%, (Figure 12). In the student 
population, 16,9% were in high school, 76,3% were graduation students, 3,4% were 
master students and 3,4% were doing PhD (Table 4). Figure 13 shows the courses 
frequented by these participants and figure 14 shows the distribution among types of 
studies. 
 Live permanently in Coimbra 42,31% of the inquired, while 30,8% live temporarily 
and 26,92% do not live in Coimbra (Figure 15). The major reason for the participants to 
live temporary in this city (91,66%), is due to studying in the university of Coimbra and 2 
(8,34%) were due to professional reasons. In relation to personal habitation, 69,2% live 
with family, 16,7% live with friends, 6,4% live alone, 3,8% live with boyfriend/girlfriend and 
3,8% live  in a student’s residential (Figure 16). 
 Concerning professions 67,9%, were student, following 7.7% were 
worker/students and 24,4% corresponded to other professions such as: DJ, worker, 
bartender, housekeeping, and musicians. 
 
 
 
Figure 11. Gender 
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Table 3. Age 
 
 
 
 
 
Figure 12. Student vs No student 
 
 
 
 
Table 4. Typology of degree 
 
Students 
Academic Degree 
Total High School Graduation Master PhD 
Count 10 45 2 2 59 
% of Total 16,9% 76,3% 3,4% 3,4% 100,0% 
Age (years) 
N Min Max 1ºQ 2ºQ 3ºQ Mean SD Median Mode 
78 18 30 20 21 24 22,18 3,66 21,00 20 
N: number of answers; Min: minimum; Max: maximum; 1ºQ/2ºQ/3ºQ: Quartiles; SD: standard deviation 
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Figure 13. Courses 
 
 
 
 
 
Figure 14. Distribution among types of studies 
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Figure 15. Residence of  participants 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Personal habitation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Professional status 
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1.2 Recreational nightlife habits 
 Data about recreational nightlife habits revealed an average of 2,09 nights out per 
week and 8,01 nights out per month. The inquiries visit in average 3,08 recreational 
spaces in each night out (Table 5).  
 In relation to the money that the participants spent per night, it varies among less 
than 5€ and more than 50€. However, the majority of participants spend 10€ per night 
(Figure 18). 
 
Table 5. Recreational nightlife habits 
 
 
 
 
 
 
Figure 18. Money spent per night 
 
 
 
Recreational nightlife habits 
 N Min Max Mean SD Mode Median    
Nights out per week 78 0 7 2,09 1,531 1 2,00 
Nights out per month 78 0 30 8,01 5,669 4 8,00 
Recreational spaces 78 0 10 3,08 1,618 3 3,00 
 
N: number of answers;   Min: minimum;   Max: maximum;   SD: standard deviation 
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1.3 Health information  
 The participants of this study weigh, in average, 69,71 kilograms and height, in 
average, 1,7372 meters (Table 6). The majority of participants (78,2%) do not have health 
problems. Among the participants that have health problems (21,8%), about half of them 
were not taking medication. All participants who were taking medication said that it was 
prescribed by his doctor (Table 7). The last food intake by participants was, in average, 
4,85 per hours ago (Table 6). 
 
Table 6. Health information 
 
 
Table 7. Health problems and use of medication 
 
 
Use of medication 
Health Problems Use Prescription Medication 
No Yes Total No Yes Total 
 No Count 61 8 69 0 0 0 
% of Total 78,2% 10,3% 88,5% 0% 0% 0% 
Yes Count 0 9 9 0 9 9 
% of Total 0% 11,5% 11,5% 0% 100% 100% 
                  Total Count 61 17 78 0 9 9 
% of Total 78,2% 21,8% 100,0% 0% 100% 100% 
 
1.4 Problems due to use of psychoactive substances 
 Regarding to health problems related to the use of drugs, 19 (6,8%) of the 
individuals affirmed that already had problems with the use of psychoactive substances. 
The majority of the participants, 8 (42,11%), were injured and 4 (21,05%) got sick. Only 2 
people (10,53%) had a sexual regret, 1 (5,26%) had family or friends problems, 1 (5,26%) 
had a crisis anxiety or a mental disturbance, 1 (5,26%) had a road accident and 2 
(10,53%) have already experienced all of these problems. 
Health information 
 N Min Max Mean SD Mode Median    
Weight 78 45 115 69,71 13,234 70 70,00 
Height 78 1,52 1,93 1,7372 0,08842 1,8 1,7400 
Last feed administrated 
(hours ago) 
78 1 9 4,85 2,330 8 5,00 
N: number of answers;   Min: minimum;   Max: maximum;   SD: standard deviation 
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 In respect to the influence of psychoactive substances in social behavior of the 
78 participants, 12,82% answered that the use of drugs interfered to their friendship; 
25,6% had already driven under the effect of psychoactive substances and 14,1% had 
being involved in conflicts with authority due to drug use (Table 8). 
 In relation to the major risk associated with going out at night, only 7,69% of the 
inquiries answered “no risk”, 17,95% mentioned the alcohol effects, 16,67% traffic 
accidents, 14,10% drug effects, 11, 54% alcohol and drug effects and physical violence, 
7,69% sexual violence, 5,13% to get unconsciousness, 3,85% stealing or robbery, 2,56% 
the drug users and 1,28% the police (Figure 19). 
 
Table 8. Problems due to use of psychoactives substances 
 
  Frequency Percent Valid Percent Cumulative Percent 
Influence of psychoactive 
substances in friends 
relations 
No 68 87,2 87,2 87,2 
Yes 10 12,8 12,8 12,8 
Total 78 100,0 100,0  
Drive under psychoactives 
substances 
No 58 74,4 74,4 74,4 
Yes 20 25,6 25,6 25,6 
Total 78 100,0 100,0  
Problems with authority 
due to use of psychoactive 
substances 
No 67 85,9 85,9 85,9 
Yes 11 14,1 14,1 14,1 
Total 78 100,0 100,0  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Perception of risk 
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1.5 Drug abuse patterns  
 The psychoactive substance more used by young people in recreational settings 
was alcohol (87,2%), followed by tobacco (64,1%). Regarding to illegal psychoactive 
substances, cannabis was the most used drug (19,2%), followed by cocaine and 
amphetamines (2,6%), LSD and smartshop substances (1,3%). In this study, it was not 
detected the use of other illicit drugs such as: ecstasy, psilocybin, mescaline, heroin, 
GHB, or flunitrazepam. On the other hand, cathinones or synthetic cannabinoids may fall 
in the 1,3% use of smartshop substances (Table 9). 
 The 87,2% of participants who used alcohol, in average, consumed 5,40 
fermented drinks and 3,16 distilled drinks (Table 9). All of the 64,1% of participants that 
used tobacco, consumed smoked tobacco. These young people smoke in average 14,84 
cigars when go out at night. The brand of cigarettes more common was Marlboro with 
20,51%, following Camel with 12,8%, and 10, 28% used other brands of cigars (Figure 
20).  
 Among the 19,2% individuals who used cannabis, 6,41% do not smoke one 
complete cannabis cigarette, but only smoke, in average, 4,2 raisins. The rest of them, 
smoked in average 2,73 cigarettes (Figure 21). The 2,6% of people who used cocaine, in 
average sniffed 2 lines, and 1,3% shared material. All users of cocaine sniffed this 
psychoactive substance. About the 2,6% users of amphetamines, 1,3% ingested in 
average 1 pill, and 1,3% smoked in average 2 raisins. The only one user of LSD (1,3%) 
used one stamp in that week. The only one user of smartshop substances (1,3%) 
ingested one pill named creatine (Table 9). 
 85,9% of the participants do not use substances for relaxing in the end of the night, 
although 6,41% use cannabis, 5,13% use medicines (2,56% valium, 1,28% guronsan 
1,28% alprazolam),1,28% use cocaine and 1,28% use tobacco for sleeping well (Figure 
22). 
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Table 9. Psychoactive substances used by participants during that week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Brands of cigarettes used by participants 
Use of Psychoactive Substances 
 Frequency 
(Total) 
Percent 
(Total) 
Route  
Administ. 
Min Max Mean  SD 
Tobacco       Cigarettes 50 64,1% Smoked 2 70 14,84 15,403 
Alcohol        Fermented 
                        Distilled 
 
68 
 
87,2% 
Ingested 
Ingested 
0 
0 
20 
13 
5,40 
3,16 
5,303 
3,732 
Cocaine               Lines 2 2,6% Sniffed 1 3 2,00 1,414 
Amphetamines      Pills 
                           Raisins 
 
2 
 
2,6% 
Ingested 
Smoked 
1 
2 
1 
2 
1,00 
2,00 
0 
0 
Ecstasy 0 0%  0 0 0 0 
Cannabis      Cigarettes 
                          Raisins 
15 19,2% Smoked 
Smoked 
0 
2 
10 
8 
2,73 
4,20 
3,348 
2,280 
LSD                   Stamps 1 1,3% Ingested 1 1 __ __ 
Ketamine 0 0%  0 0 0 0 
Psilocybin 0 0%  0 0 0 0 
Mescaline 0 0%  0 0 0 0 
Heroin 0 0%  0 0 0 0 
GHB 0 0%  0 0 0 0 
Flunitrazepam 0 0%  0 0 0 0 
Cathinones 0 0%  0 0 0 0 
Synthetic 
Cannabinoids 
0 0%  0 0 0 0 
Smartshops           Pills 
Substances 
1 1,3% Ingested 1 1 __ __ 
Administ: Administration  Min: minimum;   Max: maximum;   SD: standard deviation 
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Figure 21. Number of cannabis cigarettes 
 
 
 
 
 
Figure 22. Use of psychoactive substances for sleeping well 
 
1.6 Drug abuse patterns and socio-demographic characteristics  
 With the objective of analyzing the influence of gender on drug abuse patterns, it 
was used the non parametric test of Pearson Chi-Square. For the psychoactive substance 
tobacco, 28(35,9%) are no smokers, being 8 (38,1%) females and 20(35,1%) males. On 
other hand, 50(64,1%) of the total participants are smokers, being 13(61,9%) females and 
37 (64,9%) males. Using the non parametric test of Pearson Chi-Square p=0,806, there 
are no statistically significant differences between gender and tobacco smoking (Table 
10).  For alcohol, 10 participants (10,8%) do not consume alcohol, being 3 (14,3%) 
females and 7(12,3%) males. On the other hand, 68(87,2%) of the total participants 
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consume alcohol, being 18(87,5%) females and 50 (87,7%) males. Using the non 
parametric test of Pearson Chi-Square p=0,814 there are no statistically significant 
differences between gender and consumption of alcohol (Table 11). Concerning cannabis, 
15(19,2%) of the total participants used cannabis, being 1(4,8%) females and 14 (24,6%) 
males. Although it is not possible to determine statistically the influence of gender in 
cannabis use, it is possible to observe that there is an association between male gender 
and cannabis use (Table 12). When analyzed the number of tobacco cigarettes, we can 
observe that males (average 17,22) consume more cigarettes than females (average 
8,08). The same occurs with alcohol, the mean of fermented and distilled drinks being 
higher in males (average 6,43 and 3,76 respectively) than in females (average 2,61 and 
1,56 respectively)  (Table 13).  
 
Table 10. Gender vs Tobacco 
 
Non parametric test of Pearson Chi-Square 
p=0,806 
Gender 
Total Female Male 
Tobacco No Count 8 20 28 
% within Gender 38,1% 35,1% 35,9% 
Yes Count 13 37 50 
% within Gender 61,9% 64,9% 64,1% 
Total Count 21 57 78 
% within Gender 100,0% 100,0% 100,0% 
 
 
 
Table 11. Gender vs Alcohol 
 
Non parametric test of Pearson Chi-Square 
p=0,814 
Gender 
Total Female Male 
Alcohol No Count 3 7 10 
% within Gender 14,3% 12,3% 12,8% 
Yes Count 18 50 68 
% within Gender 85,7% 87,7% 87,2% 
Total Count 21 57 78 
% within Gender 100,0% 100,0% 100,0% 
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Table 12. Gender vs Cannabis 
 
 
 
 
 
 
 
 
 
 
 
Table 13. Gender vs number of cigarettes or drinks 
 
 
 
 
 
  
  
 
Comparing the drug abuse patterns with the professional situation of the 
participants, we can conclude that, for tobacco and alcohol, the results obtained using the 
test of Pearson Chi-Square did not provide statistically significant differences between the 
drug and the professional situation (p=0,478). However, when consumption of cannabis 
and professional situation were compared, we observed that the majority, 9 (60%), were 
students and the others are musician 1(10%), DJ 1(10%) and other professions. Applying 
the same probabilistic test, the results are statistically significant with p=0,029. For 
cocaine due to the small size of the samples (2 individuals) is not possible to determine 
the statistic probability (Table 14). 
 
 
 
 
 
Gender 
Total Female Male 
Cannabis No Count 20 43 63 
% within Gender 95,2% 75,4% 80,8% 
Yes Count 1 14 15 
% within Gender 4,8% 24,6% 19,2% 
Total Count 21 57 78 
% within Gender 100,0% 100,0% 100,0% 
 
 Gender N Mean Std. Deviation Std. Error Mean 
NºCigarettes Female 13 8,08 4,536 1,258 
Male 37 17,22 17,139 2,818 
NºFermented Female 18 2,61 2,933 ,691 
Male 49 6,43 5,624 ,803 
NºDestilled Female 18 1,56 2,148 ,506 
Male 49 3,76 4,024 ,575 
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Table 14. Professional Situation vs use of psychoactive substances 
 
Tobacco Alcohol Cocaine Cannabis 
Total No Yes No Yes No Yes no yes 
Professional 
Situation 
Bartender Count 0 2 0 2 2 0 2 0 2 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
DJ Count 0 3 1 2 3 0 2 1 3 
% within 
Tobacco 
,0 ,1 ,1 ,0 ,0 ,0 ,0 ,1 ,0 
Factory of 
electric motors 
Count 1 0 0 1 1 0 1 0 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Housekeeping Count 2 0 0 2 2 0 2 0 2 
% within 
Tobacco 
,1 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Locksmith Count 0 1 0 1 1 0 0 1 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,1 ,0 
Musician Count 1 0 0 1 0 1 0 1 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,5 ,0 ,1 ,0 
Painter Count 0 1 0 1 1 0 1 0 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Public works Count 0 1 0 1 1 0 1 0 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Real Estate 
Agent 
Count 0 1 0 1 1 0 0 1 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,1 ,0 
Security Count 1 0 0 1 1 0 1 0 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Soldier Count 0 1 0 1 1 0 1 0 1 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Student Count 21 32 5 48 52 1 44 9 53 
% within 
Tobacco 
,8 ,6 ,5 ,7 ,7 ,5 ,7 ,6 ,7 
Student/Worker Count 2 4 3 3 6 0 6 0 6 
% within 
Tobacco 
,1 ,1 ,3 ,0 ,1 ,0 ,1 ,0 ,1 
Unemployed Count 0 2 0 2 2 0 0 2 2 
% within 
Tobacco 
,0 ,0 ,0 ,0 ,0 ,0 ,0 ,1 ,0 
Worker Count 0 2 1 1 2 0 2 0 2 
% within 
Tobacco 
,0 ,0 ,1 ,0 ,0 ,0 ,0 ,0 ,0 
 
 
Analyzing the household where the participants live with the drug abuse patterns, 
in relation to tobacco there are no statistically significant differences (p=0,358). However, 
when we analyse alcohol consumption, 48 (70%) who drink alcohol live with family and 
11(20%) live with friends, being the P value 0,73. Therefore, there is not a positive 
68 
 
correlation between the household and use of alcohol. Among the users of cocaine, 
1(10%) lives alone and 1(10%) lives with family. Among the users of cannabis, the 
majority live with family 9(60%) and 4(30%) live with friends, do not having any 
association between household and use of cannabis (P value = 0,385) (Table 15). 
 
Table 15. Household vs use of psychoactive substances 
 
1.7  Drug abuse patterns and recreational nightlife habits 
 The recreational habits among young people are closely related with use of 
psychoactive substances. Analyzing the graph about frequency of nights out per week 
and polyusers (Figure 23), we can observe that participants who go out until 4 times in the 
week, use in general 2 types of psychoactive substances, being that females are entirely 
in these group. The participants (all males) who frequent recreational spaces more than 4 
times a week, in their majority use three types of psychoactive substances, being at least 
one illegal. The users of four or more types of psychoactive substances, being at least 2 
illegal, go out until 3 times per week. 
 In relation to the gender, females who use only one type of psychoactive 
substance go out until 2 times at week, while females who use 2 types of psychoactive 
substances go out more times per week (between1 and 4 times). Males go out more times 
per week than females, even those who do not use or only use one type of psychoactive 
substance. (Figure 23). 
Household 
Tobacco Alcohol Cocaine Cannabis 
Total No Yes No Yes No Yes no yes 
 Alone Count 3 2 1 4 4 1 3 2 5 
% within 
Tobacco 
,1 ,0 ,1 ,1 ,1 ,5 ,0 ,1 ,1 
Friends Count 5 8 2 11 13 0 9 4 13 
% within 
Tobacco 
,2 ,2 ,2 ,2 ,2 ,0 ,1 ,3 ,2 
Family Count 18 36 6 48 53 1 45 9 54 
% within 
Tobacco 
,6 ,7 ,6 ,7 ,7 ,5 ,7 ,6 ,7 
Boyfriend/
Girlfriend 
Count 0 3 1 2 3 0 3 0 3 
% within 
Tobacco 
,0 ,1 ,1 ,0 ,0 ,0 ,0 ,0 ,0 
Student's 
Residenti
al 
Count 2 1 0 3 3 0 3 0 3 
% within 
Tobacco 
,1 ,0 ,0 ,0 ,0 ,0 ,0 ,0 ,0 
Total Count 28 50 10 68 76 2 63 15 78 
% within 
Tobacco 
1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 
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Figure 23. Recreational nightlife habits and polyconsumption 
1.8 Drug abuse patterns and health information 
  Using the non-parametric test of Pearson Chi-Square, there are statistically 
significant differences between use of medications and polyusers (p=0,002). Among the 
participants who use medications prescribed by their doctor, only two of them do not use 
more than one type of psychoactive substances. The majority of them, uses 2 types of 
psychoactive substances, even when they have taken medications. One individual who 
had taken medications use 3 types of psychoactive substances, being at least one of 
them illegal (Table 16).  
 
Table 16. Use of medication and use of psychoactive substances 
 
Use of Medication Polyusers 
Total 0 1 2 3 4 
 No 0 24 30 10 5 69 
Yes 2 2 4 1 0 9 
                                Total 2 26 34 11 5 78 
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1.9 Drug abuse patterns and problems due to use of psychoactive substances 
 Analysis of the relation between health problems (as injured, get sick, have a 
sexual regret, anxiety crisis, friends/family problems and traffic accident) and use of 
substances indicates, in a general, that there is an upper risk for health problems among 
the users of psychoactive substances. In relation to tobacco, the users have a light 
increased risk of health problems, with an odds ratio of 1,288. In relation to alcohol, the 
participants who use alcohol have clearly more problems than those do not drink. In 
relation to cocaine, the odds ratio is 3,22, which means that the users of cocaine have 
three times more health risk than no users. The cannabis users have 2,56 times more 
health risk than no users (Table 17). 
Table 17. Health problems due to use of psychoactive substances vs drug abuse patterns 
 In relation to other problems, the users of alcohol have a light risk of problems in 
their personal relations with a odd ratio of 1,373, while cocaine users have an higher risk, 
with an odds ratio of 7,44. The users of cannabis have a double risk of problems in their 
personal relations than no users (odds ratio 2,00).  
 There is a high relation between the use of tobacco and driving problems with a 
contingency coefficient of 0,923. The risk of driving problems associated with the 
consumption of alcohol is of 1,5 (odds ratio). The users of cocaine have an increased risk 
of driving problems 3.00 times more than no cocaine users (odd ratio 3,00). The users of 
cannabis have 1,6 more risk of driving problems than no users. In relation to problems 
with authority, the cocaine users have the highest risk concerning this issue with an odds 
ratio of 6,6, following by cannabis and alcohol consumers with 1,7 and 1,5 odds ratio, 
respectively (Figure 18). 
 
 
 
 
 
Problems due to use of 
psychoactive substances 
Tobacco Alcohol Cocaine Cannabis 
Total No Yes No Yes No Yes no yes 
No Count 22 37 7 52 58 1 50 9 59 
% within Tobacco ,8 ,7 ,7 ,8 ,8 ,5 ,8 ,6 ,8 
Yes Count 6 13 3 16 18 1 13 6 19 
% within Tobacco ,2 ,3 ,3 ,2 ,2 ,5 ,2 ,4 ,2 
Total Count 28 50 10 68 76 2 63 15 78 
% within Tobacco 1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 
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Table 18. Personal, driving issues, and problems with authorities due to use of 
psychoactive substances. 
 
 
 
 
 
 
 
 
 
 
 
 
Influence of psychoactive substances 
in: 
Tobacco Alcohol Cocaine Cannabis 
Total No Yes No Yes No Yes no Yes 
Friend Relation No Count 24 44 9 59 67 1 56 12 68 
% within Tobacco ,9 ,9 ,9 ,9 ,9 ,5 ,9 ,8 ,9 
Yes Count 4 6 1 9 9 1 7 3 10 
% within Tobacco ,1 ,1 ,1 ,1 ,1 ,5 ,1 ,2 ,1 
Driver No Count 21 37 8 50 57 1 48 10 58 
% within Tobacco ,8 ,7 ,8 ,7 ,8 ,5 ,8 ,7 ,7 
Yes Count 7 13 2 18 19 1 15 5 20 
% within Tobacco ,3 ,3 ,2 ,3 ,3 ,5 ,2 ,3 ,3 
 Authority 
problems 
No Count 24 43 9 58 66 1 55 12 67 
% within Tobacco ,9 ,9 ,9 ,9 ,9 ,5 ,9 ,8 ,9 
Yes Count 4 7 1 10 10 1 8 3 11 
% within Tobacco ,1 ,1 ,1 ,1 ,1 ,5 ,1 ,2 ,1 
Total Count 28 50 10 68 76 2 63 15 78 
% within Tobacco 1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 1,0 
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1. Implementation of methodologies for the identification and quantification of 
psychoactive substances in biological samples   
1.1 Analysis of ethanol  
1.1.1 Pre-treatment of samples  
 Ethanol is a volatile compound whose detection and quantification in biological 
matrices can be made with a direct injection, using a capillary column, in the gas 
chromatography with flame ionization detection (GC–FID). In this work, the analysis of 
ethanol in blood samples, and in oral fluid samples, were realized according to method 
previously published method (Pontes et al., 2009). This validated method was chosen 
because is a rapid and efficient method that requires only the addiction of triton-x100 
solution (containing acetonitrile in its composition) for the pre-treatment of the samples. 
This solution was used to dilute the blood and oral fluid matrices. 
1.1.2 Detection by gas-chromatography flame ionization detector 
 Gas-chromatography flame ionization detector has a high sensitivity, uniform 
response to hydrocarbons, and a broad linear range that have made the flame ionization 
detector (FID) one of the most widely used detector in gas chromatography. The FID 
response of hydrocarbons is proportional to the mass of carbon present in the sample 
(Jorgensen et al., 1990). 
 In this work, interferences were ruled out by verifying the absence of peaks in the 
retention time of ethanol. The retention time for ethanol and IS (1- propanol) were 3.06 
min and 5.08 respectively. The acetonitrile, integrant part of triton-x 100 solution has as 
retention time of 3.71 min (Figure 24). 
 
Figure 24. Representative chromatograms obtained from blood sample. The retention 
time for ethanol, IS (1- propanol) and acetonotrile were 3.06, 5.08 and 3.71 min 
respectively. 
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1.1.3 Selectivity of the method 
 The GC-FID chromatograms of spiked samples were compared with the 
chromatograms obtained with a blank blood/oral fluid sample. No interference peaks were 
detected in the retention times of ethanol neither in blood sample (Figure 25) nor in oral 
fluid sample (Figure 26). 
Figure 25. Representative chromatograms obtained from blood sample. The figure A 
represents a blank blood sample without ethanol. The figure B represents a blood sample 
containing ethanol. 
 
 
Figure 26. Representative chromatograms obtained from oral fluid sample. The figure A 
represents a blank oral fluid sample without ethanol. The figure B represents an oral fluid 
sample containing ethanol. 
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1.1.4 Calibration curve 
 In this work, the calibration curve of ethanol for blood samples was evaluated in 
the range of 0 g/L to 2.4 g/L. This calibration curve was obtained with six concentrations 
(0; 0.15; 0.30; 0.60; 1.20; 2.40 g/L). For oral fluid samples, the calibration curve was 
evaluated in the range of 0 mg/L to 0.60 g/L, and the calibration curve was obtained with 
five concentrations (0; 0.0375; 0.075; 0.30; 0.60 g/L). All blood/oral fluid samples were 
analyzed according to the procedure previously described (Chapter I) respectively. The 
weighted least squares regression equations and coefficients of correlation were 
calculated from these curves. The GC-FID chromatogram peak area ratios of ethanol/IS 
were determined to establish calibration equation (Figure 27). 
 
 
Figure 27. Calibration curves for blood and oral fluid samples. Plotted peak areas of the 
ethanol/IS peak areas versus concentrations (0; 0.15; 0.30; 0.60; 1.20; 2.40 g/L) for blood 
samples and (0; 0.0375; 0.075; 0.30; 0.60 g/L) for oral fluid samples 
 
The method was linear at the concentration range established, with determination 
coefficients (r2) greater than 0.99 for the calibration curves of THC for blood and oral fluid 
samples (Table 19).  
Table 19. Blood and oral fluid linear regressions analysis of ethanol standard solutions. 
Type of samples Y=mx+b R
2
 Concentration range 
(g/L) 
Blood Y=8.5735x +0.1575 0.9989 0-2.4 
Oral Fluid Y=8.127x +0.0896 0.9987 0-0.6 
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2.1 Analysis of 9-THC 
2.1.1 Sample preparation for gas-chromatography mass spectrometry 
2.1.1.1 Extraction of samples 
In toxicological analysis, plasma or blood are the ideal samples for the detection 
and quantification xenobiotics. The concentrations of many xenobiotics, and their 
metabolites, tend to be higher in blood, thereby facilitating detection (Dinis-Oliveira et al., 
2010). However, blood is a complex biological matrix containing many interferents, such 
as proteins, hormones and blood cells. The separation and elimination of this interferents 
is an important step for obtain good results. Actually the analyses of cannabinoids in 
biological samples are continually being developed in forensic toxicology. The mainly 
methods that are described for the extraction of cannabinoids from blood include solid 
phase extraction (SPE) (REF)  and liquid–liquid extraction (LLE) (Andrews and Paterson, 
2012). In this case the liquid-liquid extraction was quick, efficient and more favorable in 
9-THC analysis over SPE due to the nature of the sample matrix. 
Using SPE method to extract 
9-THC in blood samples, it was obtained a bad 
peak resolution and the compounds were not well separated (Figure 28(1)). However, in 
LLE the best results were obtained in THC analysis. (Figure 28(2)). The chosen LLE 
method for this study proved to be simple and rapid in the preparation of samples prior to 
analysis by GC-MS. 
 
 
Figure 28. Different methods of 9-THC extraction in blood samples. 1. Chromatogram of 
SPE method showing a bad peak resolution. 2. Chromatogram of LLE method showing a 
good peak resolution and good separation of the compounds. 
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2.1.1.2 Derivatization 
 9-THC has a tri-cyclic 21- carbon structure without nitrogen and with two chiral 
centers in transconfiguration. It is a volatile viscous oil with high lipid solubility and low 
aqueous solubility and a pKa of 10.6 (Sharma et al., 2012). Due to the presence of only 
one hydroxyl group and its long chemical structure, it was necessary to test different 
compounds, times and temperatures of derivatization for obtaining the best peak 
resolution.  
 In this study, 9-THC was derivatized by silylation, reacting with BSTFA and 
TMCS. BSTFA is the silylation reagent that reacts with 9-THC and replaces active 
hydrogens with a –Si(CH3)3 (trimethylsilyl) group (Figure 29). TMCS increases the 
reactivity of BSTFA. 
 
 
The derivatization process using BSTFA +1%TMC for 1h at 70 ºC, allowed an 
increase in 9-THC volatility, improving the thermal stability and consequently the 
detectability of the derivative (Figure 30) 
 
 
Figure 30. 9-THC with and without the derivatization step. 1. Chromatogram of 9-THC 
without derivatization step showing a bad peak resolution. 2. Chromatogram of 9-THC 
with derivatization step showing a good peak resolution. 
Figure 29. Derivatization reaction of THC 
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2.2 Method Validation of 9-THC 
2.2.1 Detection by gas-chromatography mass spectrometry  
 Preliminary tests were performed to determine the best conditions of 
chromatographic separation and detection in order to obtain the best peak resolution and 
separation of 9-THC. In the chromatogram, it is possible to identify the peak of 9-THC. 
 
 
 
 
 
 
 
 
Figure 31. Mass spectrum of 9-THC without derivatization. 
Figure 32. Mass spectrum of 9-THC derivatized. 
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Based on mass spectrum of each peak, for 9-THC the first peak represents 9-
THC without derivatization (Figure 31) the second peak shows 9-THC derivatized (Figure 
32). For 9-THC, three ions were used. The most abundant ion m/z 386 was used for 
quantification and the other ions m/z 371 and 315 were used for the proper identification. 
2.2.2 Selectivity 
 The GC-MS chromatograms of spiked samples were compared with the 
chromatograms obtained with a blank blood sample. No interference peaks were detected 
in the retention times of 9-THC (Figure 33) or in the IS and selected ions (Figure 34). 
 
 
Figure 33. Reconstructed GC-MS (SIM mode) chromatogram of a blank blood sample 
(1000 ng/mL) and THC (m/z 386+371+315). 
 
 
Figure 34. Reconstructed GC-MS (SIM mode) chromatogram of a blank blood sample 
(1000 ng/mL) and internal standard (m/z 105+182). 
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2.2.3 Linearity 
 In this work, the 9-THC linearity studies were evaluated in the range of 0 ng/mL to 
1000 ng/mL. This calibration curve was obtained with nine concentrations (0, 1, 5, 10, 25, 
50, 100, 500, 1000 ng/mL). The blood samples were analyzed according to a previously 
described procedure (Chapter I). The weighted least square regression equation and 
coefficient of correlation were calculated from this curve. The GC-MS chromatogram peak 
area ratios of 9-THC/IS were determined to establish calibration equation (Figure 35). 
 
 
Figure 35. 9-THC calibration curve. Plotted peak area of the 9-THC/IS peak area versus 
concentrations (0, 1, 5, 10, 25, 50,100, 500, 1000 ng/mL). 
 
The method was linear at the concentration range established, with determination 
coefficients (r2) greater than 0.99 for the calibration curve of 9-THC (Table 20). 
  
Table 20. Blood linear regression analysis of 9-THC standard solutions (0-1000 ng/mL). 
 
Psychoactive 
substance 
Y=mx+b R
2
 Concentration range 
(ng/mL) 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
 
THC 
 
Y=0.0006x -0.0001 
 
0.9996 
 
0-1000 
 
0.23 
 
0.69 
LOD, limit of detection; LLOQ, lower limit of quantification 
 
 
 
 
 
 
y = 0,0006x - 0,0001 
R² = 0,9996 
-0,1 
0 
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0 200 400 600 800 1000 1200 
THC calibration curve 
ng/mL 
area 
THC/IS 
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2.2.4 Limit of detection and lower limit of quantification  
The LOD is 0.23 ng/mL and LLOQ is 0. 69 ng/mL for 9-THC (Table 20). These 
results show a good capacity of this method for the quantification of 9-THC analytes, 
although these analytes were in low concentrations.  
2.2.5 Precision 
The %CV values calculated for 9-THC intra and inter-day precision studies did not 
exceed 15%, so that the developed method was considered precise (Table 21). 
2.2.6 Accuracy 
The accuracies of 9-THC were determined in the range of 98,36-106,59% (Table 
21), which are within the proposed acceptance limits for this parameter (100 ± 15%). 
2.2.7 Recovery 
At three different concentrations of 9-THC (10, 100, 1000 ng/mL), the results 
obtained indicated an efficient clean-up procedure, with extraction recoveries in the range 
of 102.95 to 108.68%. The recoveries are within the proposed acceptance limits for this 
parameter (100 ± 20%) (Table 21).  
2.2.8  Reproducibility 
At five equal concentrations of 9-THC (100 ng/mL), the results obtained did not 
exceed 15% of coefficient of variation. The reproducibility of 9-THC developed method 
was considered reproducible (Table 21). 
 
Table 21. Precision, accuracy, recovery and reproducibility (%) for THC. 
 
Analytes Concentration 
(ng/mL) 
Intra-day 
precision 
(%, n=3) 
Inter-day 
precision 
(%,n=3) 
Accuracy 
(%, n=3) 
Recovery 
(%) 
Reproducibility 
(%) 
 
 
THC 
 
10 
100 
1000 
 
4.25 
0.34 
0.64 
 
7.03 
1.61 
3.29 
 
98.35 
101.17 
106.59 
 
108.68 
102.95 
105.09 
 
 
6.98 
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2.3 Analysis of amphetamines 
 The characteristic ions that allow identification of amphetamines are: 44 
(amphetamine, MDMA, MDA) and 58 (methamphetamine, MDMA). Comparing the 
chromatograms obtained from the samples suspected to have amphetamines, with GC-
MS program (NIST), no amphetamines were identified. 
. 
2.4 Analysis of cocaine 
 The screening tests have an absorbent material of each test strip that carries the 
biological sample across the strip at a specific speed. The biological samples have special 
molecules that interact with drug-specific antibodies. These antibodies only react to 
metabolites for the specific drug being test. If the biological sample contains the specific 
drug metabolites, the special molecules react with antibodies and do not give a color, as 
happened with the positive cocaine control sample (Figure 36 cocaine). However, if the 
biological sample does not contain cocaine metabolites, the molecules turn a color, as 
happened with sample 37 and 38 (Figure 36). The tests have also a control line (C) at the 
top of the test strip, where a reagent makes the molecules turn a color to indicate that the 
test is working properly. If the control line does not appear, it means that the test is not 
working properly. In this study, the control line appears, that means that the test worked 
well, however another the line T(test) appears. Therefore cocaine levels were below those 
detectable by this method (Figure 36, sample 37 and 15).  
 
 
 
 
 
 
 
 
 
 
Figure 36. Cocaine screening test 
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Chapter V 
Application of the GC-MS and GC-FID  
methods to blood and oral fluid samples collected 
from the volunteers participating in this study 
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1. Application of GC-FID for detect ethanol in biological samples 
The method described by Pontes et al. (2009), with some modifications (shown in 
chapter II), was applied to the ethanol quantification in blood and in oral fluid samples, 
collected from young adults frequenting nightclubs and that participated voluntarily in this 
study. Sixty nine blood samples, 17 oral fluid samples, and 46 exhaled air samples were 
obtained from these participants. With the objective to compare the results of different 
matrices, in 9 participants, both types of biological matrices (blood and oral fluid) were 
collected and analyzed. In some participants samples of exhaled air, to compare this 
result with the results of biological samples, were also collected. Concerning ethanol 
quantification, 64 blood samples have had positive results and 5 others gave negative 
results Eighteen oral fluid samples were positive, and 1 was negative for ethanol. Forty 
five exhaled air samples were positive and 1 was negative for ethanol. 
The analysis of ethanol revealed concentrations ranging from 0 to 2,69 g/L for 
blood samples, from 0 to  1,18 g/L for oral fluid samples, and from 0 to 3,88 g/L for 
exhaled air. GC-FID chromatograms of blood and oral fluid samples (from subject number 
25) are shown in Figure 37. 
 
 
Figure 37. GC-FID chromatograms obtained from a blood sample (A) and an oral fluid 
sample (B) positive for ethanol (subject number 25). The retention time for ethanol was 
3.062 min figure A and 3.055 figure B. 
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 For the correct interpretation of the results, there are some aspects that should be 
taking into account beyond the concentrations of the ethanol. There are many factors as 
physiological (age, gender, weight, height), behavioral, genetic, sociocultural and 
environmental that play a relevant role in determining the huge interindividual variability in 
the thresholds and lifetime prevalence of ethanol in biological samples (Gemma et al., 
2006). 
Physiological differences such as bodyweight, height, body surface area and total 
body water, existing between man and women contribute for toxicokinetic and 
toxicodynamic differences of psychoactive substances as alcohol, and consequently to 
differences in the concentration of ethanol in biological samples (Soldin and Mattison, 
2009). These anatomical differences between both genders (Table 22) are important 
reasons to explain the differences found between individuals that consumed the same 
drinks, exhibiting different concentrations of ethanol in biological samples. 
 
 Table 22. Anatomical differences between man and women that influence the 
concentration of ethanol in biological samples (adapted from Soldin and Mattison, 2009). 
 
 
 
 
 
 
 
 
 Genetic features involved in ethanol metabolism may also influence the 
concentration of ethanol in biological samples, at the moment of collection. The hepatic 
enzymes involved in ethanol metabolism as alcohol dehydrogenase (ADH), aldehyde 
dehydrogenase (ALDH) and microsomal P4502E1 (CYP2E1) have shown to be 
polymorphic, giving rise to altered phenotypes. Recent studies have shown the correlation 
between metabolic variability and differences in alcohol abuse-related effects (Gemma et 
al., 2006). Consequently, for the same quantity of ethanol ingested, the concentration 
found in blood or in oral fluid could be different, due to interindividual variations in alcohol 
metabolism. 
 Behavioral features, as mixture of psychoactive substances and ingested alcohol 
with empty stomach could influence the pharmacokinetics of ethanol. Alcohol is absorbed 
mainly in stomach and in small intestine. The rate of the absorption depends on the rate of 
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gastric emptying. When alcohol is ingested with empty stomach, the digestive system is 
irritated and as there is no food, the absorption of alcohol becomes more rapid. As a 
result, the blood alcohol concentration (BAC), which is the amount of alcohol in blood 
stream, increases more rapidly and the effects of alcohol are felt quicker. When alcohol is 
ingested with food, the gastric emptying is slow, the absorption of alcohol is delayed and 
peak blood alcohol concentration is reduced. The gastric emptying rate makes an 
important contribution to interindividual variations in the rate of alcohol absorption and 
therefore in the magnitude of the acute intoxications (Holt, 1981). 
 The consumption of alcohol with other drugs, legal (medications)  or illegal, causes 
pharmacokinetic interactions by altering gastric emptying or liver metabolism. Drugs may 
affect pharmacokinetics of alcohol by inhibiting gastric alcohol dehydrogenase, 
responsible for converting alcohol to aldehydes, and could cause acute intoxications 
(Fraser, 1997). 
 Beyond these interindividual factors there is other variable, the origin of the 
psychoactive substance, that was not possible to evaluate, but could affect the 
concentration of ethanol in biological samples. 
1.1 Differences between blood, oral fluid and exhaled air samples 
 Blood samples are the ideal matrix if quantitative measurements are needed 
(Dinis-Oliveira et al., 2010). However, due to the high volatility of ethanol, special mesures 
must be taken to prevent ethanol evaporation, during sample handling. For this reason 
some samples that have low concentrations of ethanol in blood, when analyzed by GC-
FID probably become false negatives (subjects number 39 and 64, table 24 chapter VI) 
For this reason, the method used by exhaled air, at the moment that the surveys are been 
collected, is the most appropriate. Exhaled air is a non-invasive method used for 
measuring concentration of volatile xenobiotic as ethanol. Breath testing eliminates the 
need for taking blood samples, and the results are immediately available (Dinis-Oliveira et 
al., 2010). Nevertheless, the ideal is to analyze alcohol in both type of matrices for outwit 
false results. 
 In this study, oral fluid samples were also used to quantify ethanol. This type of 
matrix is useful for analyzing quantitatively many xenobiotics, namely drugs of abuse 
present in saliva. For some xenobiotics as alcohol, there are a good correlation between 
the concentration found in saliva and the concentration of ethanol found in blood samples. 
Oral fluid allows detection of psychoactive substances for hours or days and it is a 
relatively non-invasive method (Dinis-Oliveira et al., 2010). However it has some 
disadvantages such as: requiring sensitive techniques and collection methods for detect 
small amounts of the xenobiotic; spitting becomes oral fluid viscous, increasing the 
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difficulty to handle the sample in the laboratory; it may also be contaminated with food and 
other debris from the mouth. For these reasons, oral fluid cannot be seen as a substitute 
for blood or urine drug testing (Drummer, 2006). 
 According to Jones (1979) (Jones, 1979) there is a relationship between ethanol 
concentration determined in oral fluid and in blood samples. This relationship is translated 
by the regression equation y=0.109+1.071x, where y is saliva ethanol concentration 
(mmol/l) and x is blood ethanol concentration (mmol/l). However, the results obtained in 
the present work, shows that oral fluid samples have lower concentration of alcohol when 
compared to blood samples. These results could be explained due to intraindividual 
reasons. Oral fluid can vary in flow rate, depending on several factors as emotional or 
hunger. The dry mouth syndrome could be caused by anxiety, lack of proper hydration of 
the individual and tobacco or THC smoke after drink, can also infuence. Hence, if the 
volume of oral fluid is less than 1 mL it is required the use of sensitive detection 
techniques. The stimulated production of oral fluid by citric acid candy, chewing gum or 
other agents will change the pH and concentration of drug in the oral fluid. This is 
scientifically proven for lower concentrations (Drummer, 2006).  
 Other important factor that should be taken into account is the local where the 
blood was collected. While in study realized by Jones, 1979, he collected capillary blood 
samples, in the present study venous blood samples were collected. Works from other 
authors showed that the ethanol present in venous blood is less concentrated than that in 
capillary blood, until onset of the post-absorptive phase of ethanol metabolism (Jones, 
1979). This could explain, in part, the results obtained in the present work. 
 Finally, the evaporation of ethanol during the sampling procedure, as happens with 
blood samples could also contribute for the final result. 
In conclusion, there is a lot of intra and inter-subject variations due to the 
technique used, the individual physiology, the characteristic of the compounds and the 
local of the sample collection, that influence the concentration of alcohol in oral fluid 
samples. 
1.2 Levels of ethanol in biological samples and its effects 
Although the concentration of ethanol in biological samples and its respective 
effects depends on many intra and inter individual factors previously described, the levels 
greater than 3-4 g/L can be fatal due to respiratory depression. The effects of alcohol 
ranging from minor impairment of motor coordination and sensation, to amnesia, loss of 
consciousness and coma when blood levels exceeding 300 mg alcohol/100mL blood (30 
mg%) (Marc and Schuckit, 2006)(Table 23). 
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Table 23. Concentrations of ethanol in blood samples and its effects (adapted from 
emedicine.medscape.com). 
BAC (g/L) Effects of ethanol 
Less than 0.5 No loss coordination and slight euphoria. 
0.6 – 0.8 Relaxation, lower inhibition, slight impairment of balance, speech and vision. 
0.9 – 1.2 Significant impairment of motor coordination, loss of good judgment and 
euphoria. 
1.3 – 3 Dysphoria, anxiety, nausea, needs of assistance and total mental confusion. 
3 – 4 Loss of consciousness. 
More than 4 Onset of coma, possible death due to respiratory depression. 
 
 Analyzing the ethanol results obtained in biological samples, it is possible to 
observe that among the 78 individuals, only 6 did not drink alcohol. Among 72 individuals, 
17 participants have less than 0.5 g/L in biological samples, 10 individuals have values of 
ethanol between 0.6 g/L and 0.8 g/L, 9 individuals have values between 0.9 g/L and 1.2 
g/L, 27 participants have values between 1.3 g/L and 3 g/L, and 9 individuals have values 
higher than 3g/L.   
 With this investigation it was possible to find high levels of alcohol consumption in 
recreational spaces, by young people. The majority of them had high blood alcohol 
concentrations that could put them at severe risk. In spite of knowing the bad 
consequences of alcohol, some of them expected to consume high quantities of alcohol 
across the course of their night out. This situation is very worrying, mainly when there is 
an increased risk of social harm associated to alcohol comsumption , particularly violence, 
intoxication, DST´s, and other risk factors. 
  Nowadays, some studies evidence the increased effectiveness of strategies to 
reduce alcohol-related harm in drinking environments, mainly in countries outside Europe. 
The measures for reducing the availability of alcohol, should focus on the restrictions of 
alcohol outlet density and increase alcohol price. These measures have significant effect, 
but are rarely used in practice (Hughes et al., 2011). 
2. Application of GC-MS  for detecting 9-THC in biological samples 
 The method validated for 9-THC was applied to analyze THC in blood and oral 
fluid samples collected from young adults who were in nightclubs and affirmed having 
used cannabis on that night or on that week. Thirteen blood samples and two oral fluid 
samples were obtained from these participants. All blood samples were positive and the 
only two oral fluid samples were negative for 9-THC. 
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 Analysis of blood samples revealed concentrations ranging from 4,69 to 62,40 
ng/mL for THC. Reconstructed full scan chromatogram of real blood sample (subject 
number 14) is shown in Figure 38. 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Reconstructed GC-MS Full Scan chromatograms obtained from blood sample 
(1) positive for THC (subject number 14) and the respective THC standard (2). THC m/z = 
386+371+315. 
As it happens with alcohol, for the correct interpretation of the THC results is 
important to take into account some aspects: i) the intra and inter individual physiology of 
each individual (age, gender, weight, height), ii) their behavioral (mixture of THC with 
other drugs, route of administration of THC), and iii) genetic features (that caused 
alterations in toxicokinetic and toxicodinamic of THC). Beyond these interindividual 
factors, there are also other variables such as: the origin of the THC and the precise 
quantity that the individuals put in their cigarettes. These factors were not possible to 
control, but could affect the concentration of Δ9-THC in biological samples. 
Behavioral features as mixture of THC with other psychoactive substances 
(alcohol or tobacco) could be dangerous, because this mixture becomes stronger and 
produces more unpredictable effects than if they were used separately. Some of the 
individuals that participated in this study, had smoked cannabis and ingested alcohol. 
Cannabinoids and alcohol activate the same reward pathways (dopaminergic system), 
and CB1 endocannabinoid receptor plays an important role in regulating the positive 
reinforcing properties of alcohol. When both are used together, its effects become 
stronger and could cause inhibit vomiting, dizziness and increased paranoia (Mechoulam 
and Parker, 2003). 
The route of administration used by THC consumers may influence the 
concentration of 9-THC in blood samples. When the drug is administrated orally, over 90 
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per cent of the dose was absorbed, and the plasma levels of metabolites of Δ9-THC 
peaked at three hours. When the drug is inhaled the metabolites peack from 10 to 140 
minutes, and the physiologic effects are felt in this moment (Lemberger et al., 1972). 
2.1 THC levels in blood samples and its effects 
 9-THC has higher lipophilicity, and therefore it is rapidly absorbed and distributed 
to tissues, passing through the mucosal epithelium into the bloodstream. When the ratio 
between blood/tissue is in equilibrium, it is possible to determinate a direct correlation of 
THC blood concentration and effect (Cone and Huestis, 1993; Huestis and Cone, 2004). 
 The study realized by Schwope et al., 2012 (Schwope et al., 2012) demonstrated 
the concentrations of THC in whole blood, after some volunteers smoked one single 
cigarette, that contained 54mg of 9-THC. After 0,25h, they had, in mean, 150μg/L of THC 
in whole blood (ranging 93 to 250 μg/L), after 4h about 13μg/L (ranging 0-32 μg/L) and 
after 6h about 8ug/L (ranging 0-27μg/L). The effects that they felt over the time were: 
“high” (66- 85 μg/L of THC in blood), good drug effects, stoned, stimulated, sedated and 
anxious (Schwope et al., 2012). The author Mattes et.al, 1994 (Huestis and Cone, 2004) 
reported that 10-15mg of THC resulted in the production of 2,5ng/mL of THC in plasma 
after 2h following administration. Also, other authors reported that THC plasma levels 
were about 14 ng/mL, in six volunteers who consumed 20mg of THC (Huestis and Cone, 
2004). Other studies, show that an estimated concentration of THC in blood samples, in a 
range of 7-29 ng/ml, causes  50% of the high effects expected for THC (Cone and 
Huestis, 1993). 
 Comparing these studies, for the range of THC from 4,69 to 62,40 ng/mL in whole 
blood, and knowing that the ratio between blood to plasma of THC concentration is 0,5, it 
is possible to conclude that the concentration of THC found in the present study, is 
sufficient for causing 50% of maximal subjective high effects. In fact, among all THC users 
that participated in this study, only 2 individuals have THC blood concentrations lower 
than 7 ng/mL. Cannabis is currently one of the most widely used illegal drugs in Coimbra’ 
recreational spaces, an important information for those involved in risk management in 
Coimbra night life.  
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Chapter VI 
Comparison of participants answers with the 
identification of psychoactive substances in 
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1. Alcohol  analyzed in biological samples vs answers about use of alcohol  
 For the question about use of alcohol during that week, 87,18% of the 
participants refered to have used alcohol while 12,82% indicated absence of alcohol 
consumption during that week (Figure 39). Following analyses of biological samples, we 
observed that 92,31% of the participants gave positive results for ethanol and only 7,69% 
gave negative results (Figure 40). Consulting the table 24, we observe that subject #64 
and #39, reported to have used alcohol, but the results where negative for ethanol. This 
could happen due to individual factors (shown in chapter V) or possible evaporation of 
ethanol during the sampling procedure. It is important to note that all of these dubious 
samples were analyzed two times separately in different days. For these reasons is very 
probable that some individuals have hidden the consumption of alcohol. Although the 
questionnaire is confidential, several of the participants showed reluctance and were 
afraid that the study becomes public, or to be shown by media. 
 
 
Figure 39. Answers given by participants about alcohol consumption. 
 
 
 
Figure 40. Biological samples analyzed by GC-FID method. 
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Table 24. Concentration of ethanol in blood, oral fluid and exhaled air samples, compared 
to responses given by the participants for the question about alcohol. 
Nº of 
samples 
Concentration 
blood samples 
(g/L) 
Concentration 
oral fluid 
samples (g/L) 
Concentration 
exhaled air 
(g/L) 
Answer about  
use of alcohol  
(Yes/No) 
Results 
obtained by GC-
FID 
1 1,56 Nc 1.74 Yes Yes 
2 1,19 Nc 1.27 Yes Yes 
3 0,139 Nc Nc No Yes 
4 Nd Nc Nc No No 
5 0,604 Nc Nc Yes Yes 
6 1,84 Nc Nc Yes Yes 
7 1,34 Nc Nc Yes Yes 
8 1,75 Nc Nc Yes Yes 
9 2,15 Nc Nc Yes Yes 
10 0,956 Nc 1.14 Yes Yes 
11 0,770 Nc 0.93 Yes Yes 
12 1,55 Nc 1.64 Yes Yes 
13 1,19 Nc 1.63 Yes Yes 
14 0,843 Nc Nc Yes Yes 
15 Nc 0,016 Nc Yes Yes 
16 0,053 Nc Nc Yes Yes 
17* 0,369 0,049 1.14 Yes Yes 
18 Nc 0,116 Nc Yes Yes 
19* 1,01 0,013 Nc No Yes 
20* 0,141 0,011 Nc No Yes 
21 Nc Nd Nc No No 
22 0,136 Nc Nc Yes Yes 
23 Nc 0,022 Nc No Yes 
24 Nc 0,019 Nc Yes Yes 
25* 1,02 0,020 1.14 Yes Yes 
26* 0,145 0,012 Nc Yes Yes 
27* 1,48 0,014 Nc Yes Yes 
28* 0,165 0,012 Nc Yes Yes 
29* 0,049 0,013 Nc Yes Yes 
30* 0,154 0,011 Nc Yes Yes 
31 0,903 Nc Nc Yes Yes 
32 0,572 Nc 1.72 Yes Yes 
33 1,83 Nc Nc Yes Yes 
34 0,105 Nc 0.70 No Yes 
35 2,07 Nc Nc Yes Yes 
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36 0,696 Nc 2.33 Yes Yes 
37 1,59 Nc Nc Yes Yes 
38 1,11 Nc Nc Yes Yes 
39 Nd Nc Nc Yes No 
40 0,782 Nc Nc Yes Yes 
41 0,890 Nc 1.52 Yes Yes 
42 1,70 Nc 2.17 Yes Yes 
43 0,181 Nc 0,69 Yes Yes 
44 0,284 Nc 1.52 Yes Yes 
45 0,136 Nc 0.63 Yes Yes 
46 2,05 Nc 3.27 Yes Yes 
47 0,041 Nc 0.66 Yes Yes 
48 1,70 Nc 3.48 Yes Yes 
49 0,059 Nc 0.39 Yes Yes 
50 0,750 Nc 3.12 Yes Yes 
51 1,46 Nc 3.88 Yes Yes 
52 0,808 Nc 3.57 Yes Yes 
53 0,389 Nc 1.12 Yes Yes 
54 0,639 Nc 1.66 Yes Yes 
55 0,611 Nc 1.59 Yes Yes 
56 0,686 Nc 1.88 Yes Yes 
57 2,07 Nc 3.12 Yes Yes 
58 0,678 Nc 1.49 Yes Yes 
59 1,33 Nc 3.27 Yes Yes 
60 1,87 Nc Nc Yes Yes 
61 0,122 Nc 1.20 Yes Yes 
62 0,512 Nc 0.9 Yes Yes 
63 0,856 Nc 1.71 Yes Yes 
64 Nd Nc Nc Yes No 
65 Nd Nc Nd No No 
66 Nd Nc Nd No No 
67 0,043 Nc 0,17 Yes Yes 
68 0,620 Nc 2,05 Yes Yes 
69 Nc 1,18 3.30 Yes Yes 
70 1,27 Nc 2,07 Yes Yes 
71 1,16 Nc Nc Yes Yes 
72 1,19 Nc 2,72 Yes Yes 
73 Nc 0,026 0,18 Yes Yes 
74 Nc 0,055 Nc No Yes 
75 Nc Nc 0,19 Yes Yes 
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2. THC  analyzed in biological samples vs answers about use of cannabis  
 For the question about use of cannabis during that week 19,23% of the 
participants reported to have used cannabis (Figure 41). Following analysis of the 
biological samples, we observed that 16,67 % of the participants were positive results for 
9-THC (Figure 42). Consulting the table 25, we observe that the subjects *21 and *23, 
reported to have used cannabis, but the results were negative for 9-THC. This could 
happen because 9-THC levels in oral fluid samples were below the detection limit of the 
method. In this case, the hypothesis of the subjects have lied is not likely. However, is 
possible they may think that the substance which they are using is cannabis, but may be 
another substance. 
 
Figure 41. Answers given by participants about use of cannabis 
 
Figure 42. Biological samples analyzed by GC-MS method 
76 2,69 Nc 3,38 Yes Yes 
77 0,861 Nc 1,49 Yes Yes 
78 1,72 Nc 2,33 Yes Yes 
Legend: * represents that ethanol was analyzed in both matrices (blood and oral fluid); red color represents 
false negatives; green color represents false positives; Nd – no detectable (below detection limit); Nc-sample 
no ceded by individual. 
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Table 25. Concentration of THC in blood samples and oral fluid samples. Answer given by 
the participants for the question about cannabis, and the respective results obtained by 
analyze of biological sample (GC-MS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Amphetamines  analyzed in biological samples vs answers about use of 
amphetamines 
 For the question about use of amphetamines during that week, only two 
participants reported to have use amphetamines. However, following analysis of the 
biological samples, it was not possible to detect any amphetamine. The amphetamines 
that participants used, may be different from those screened in the the data base (NIST), 
or the quantity found in blood samples were below the detection limit of the method. 
4. Cocaine analyzed in biological samples vs answers about use of cocaine 
 For the question about use of cocaine during that week, only two participants 
reported to have used cocaine. However following analysis of the biological samples, it 
was not possible detect cocaine by using screening tests. Again, cocaine levels could be 
below the limit of the detection of the screening tests. Screening tests give us preliminary 
results. If cocaine had done positive in blood samples, highly sensitive testing methods as 
GM-MS, should have been performed.  
THC samples Concentration 
(ng/mL) 
Answers about use of 
THC 
(Yes/No) 
Results obtained by 
GC-MS 
1 
9,02 
Yes Yes 
4 7,58 Yes Yes 
8 21,64 Yes Yes 
10 4,69 Yes Yes 
14 62,40 Yes Yes 
21* Nd Yes No 
22 14,68 Yes Yes 
23* Nd Yes No 
37 9,90 Yes Yes 
41 32,83 Yes Yes 
43 13,79 Yes Yes 
46 12,95 Yes Yes 
51 5,315 Yes Yes 
52 9,67 Yes Yes 
59 7,437 Yes Yes 
Legend: * The 21 and 23 represent the oral fluid samples; Nd – no detectable (below 
detection limit). 
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1. Discussion 
 This study intended to determine the patterns of drug abuse in recreational 
nightlife, as well as the associated sociodemographic characteristics, the recreational 
habits, the health risk and risk behaviors. A better knowledge on this subject may 
contribute to the prevention of harm associated with the excessive consumption of this 
type of substances. 
 In this study, the psychoactive substance more used among young people in 
recreational settings, in Coimbra, was alcohol (87,2%), followed by tobacco (64,1%). 
Regarding to illegal psychoactive substances, cannabis was the most used drug (19,2%), 
followed by cocaine and amphetamines (2,6%), LSD and smartshop substances (1,3%). 
Comparing this study with a similar one realized by Lomba, 2008 (Lomba et al., 2008) in 
the same city, it is possible to detect many similarities. In respect of alcohol, this author 
observed a higher consumption (95,10%)  compared to our study. However, it is important 
to take into account that, although the reported consumption of alcohol was 87,2%, 
following analysis of the biological samples, 92,3% of the participants were positive for 
ethanol in blood. The second substance used by the participants in Lomba’s study was 
tobacco, with (79,12%) followed by cannabis with (65,73%). Compared to our study, the 
consumption of cannabis was significantly higher. Additionally, although the consumption 
of this drug was 19,2%, it was only possible to detect 9-THC in 16,6% of the blood 
samples by the GC-MS method. The lower number of samples evaluated in our study 
could explain, in part, these differences. 
 In relation to the gender of participants, we observed a variance between gender 
and use of psychoactive substances. The males have tendency of use more psychoactive 
substances, as alcohol and cannabis, in higher quantities than females. This difference 
becomes more evident in relation to the use of illegal drugs as cannabis, cocaine and 
others. These results are agreement to general drug patterns in European countries. In 
fact, in these countries, one of the most used drug among young people is cannabis, 
males being those who generally use it more frequently. These differences are very 
significant in Portugal. The use of cannabis by male and female, in Europe have a ratio 
from 1.8 in Norway to 5.9 in Portugal (EMCDDA, 2005) which was confirmed in part our 
study, in which we found a ratio of 14. 
 In respect of recreational habits, we concluded that the majority of participants, 
who frequent recreational spaces with assiduity, use more psychoactive substances than 
the participants who go out occasionally. A study realized by Calafat, 2008, has the same 
finding. In his study, it was observed that as the participation in recreational nightlife 
increase, the percentage of people who did not get drunk decreases. Additionally, the 
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frequency of drunkenness increases (Calafat et al., 2008). Also in our study, was possible 
to observe a discrepancy among genders in relation to recreational habits. Males have 
more tendencies for going out more times, using more than one type of psychoactive 
substance in the same night, and use more illegal drugs than females. Studies realized by 
EMCDDA, 2005 corroborate that the number of females in relation to males is generally 
lower for illegal drugs and have lower incidence of recent or frequent patterns of drug use. 
These discrepancies between genders tend to be lower over the years (EMCDDA, 2005). 
Another study realized in two different Spanish islands (Ibiza and Mallorca), reported that 
cannabis and cocaine were more commonly used by males in both locations (Hughes et 
al., 2009). 
 Relatively to the frequency of nights out per week, Lomba, 2008, affirmed that 
inquired youngsters go out about seven days per month, mainly on weekends. This is 
concordant with our study. However, we observed a light increased in nights out per 
month, with an average of 8,01 (Lomba et al., 2008). 
 In respect of problems due to use of psychoactive substances, this study clearly 
showed that the participants who used more harmful substances, had more problems in 
all sectors. Relatively to health problems due to use of psychoactive substances, our 
study revealed higher incidence in cocaine users (odds ratio of 3,22), followed by 
cannabis (2,56). The use of alcohol was also a positive relation.  In fact, a study realized 
by Hughes, 2009 in two different locations (Malorca and Ibiza) reported that illness, 
discussions, physical fighting, unintentional injuring and needing to go to hospital, were 
more commonly reported by users of illicit drugs, especially in Ibiza. This fact could occur 
due to drug patterns in Ibiza have revealed to be relatively high, when compared with 
studies in other places, as in Portugal or whole Spain. In contrast, the drug patterns in 
Malorca had more concordance to our study. The number of cocaine users was 7,5% and 
ecstasy was 4% (Hughes et al., 2009). 
 Another subject that is associated with the consumption of psychoactive 
substances is the risky sexual behavior. Dowing, 2010 reported a comparative cross-
sectional between Germany, British and Spanish users. She concluded that the main 
factor for 34,1% of the participants contributing for sex on holiday, was high levels of 
drunkenness (Dowing et al., 2010). However, in your study this data does not have 
statistic relevance. Only one user reported to have had a sexual regret due to use of 
psychoactive substances. This could happen due Coimbra is not a characteristic touristic 
city. In fact, the number of touristic people in our study was much reduced.  
 Driving under influence of psychoactive substances and related driving-related 
problems, are also relevant subjects in our study. It is known that alcohol and cannabis 
users have an increased risk of 1,5x and 1,6x of having driving-related problems, 
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respectively, while  cocaine users have a 3x increased risk. In our study, we verified that 
25,6% of the participants have already driven under influence of psychoactive 
substances.. These results are in partial agreement with the study published by Calafat, 
2008, in which he observed a higher number of participants that had already driven drunk, 
or drugged (65,2%) (Calafat et al., 2008). 
  Nowadays, several authors have addressed some interventions that could be 
implemented in recreational spaces, with objective to reduce harm associated with 
recreational nightlife venues. Calafat, 2012, is one of these authors that highlight the 
importance of regulating standards that should be implemented in European recreational 
settings. For this author, the use of preventive interventions including venue management, 
underage checkouts, staff training and collaboration with the police, are some of 
prevention standards that could exist in nightlife industry (Calafat et al., 2012). In fact, all 
of these measures could implemented; however for many countries, including Portugal, it 
means more costs. Nevertheless, to ensure promotion of health and safety in nightlife 
spaces, risk assessment and risk control are lifesaving issues that should become an 
incentive to each and every one of us. 
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Conclusion and future perspectives 
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1. Conclusion 
I. Drug abuse patterns in Coimbra recreational nightlife was monitored in this work 
through the use of a survey and collection/analysis of biological samples. 
 
II. Although this is a pilot study with only 78 samples, it was possible to obtain significantly 
different data. 
 
III.  In general males go out with more frequency, using more psychoactive substances, 
both in quantity as in diversity, than females.  
 
IV. Alcohol was the most used psychoactive substance (87,2%), followed by tobacco 
(64,1%), cannabis (19,2%), cocaine and amphetamines (2,6%) and finally LSD and 
smartshop substances (1,3%). 
 
V.  Males have more tendencies to be polyusers. 
 
VI. Cocaine users have the highest risk for health problems perceptive to the users, 
followed by cannabis, alcohol and finally tobacco. 
 
VII. Relatively to biological samples, ethanol was the substance that has more 
discordance, comparing to the surveys. 92,31% of the participants gave positive results 
for ethanol while only 87,18% of them answered positively for the consumption of 
alcohol.  
 
VIII. The THC results show more concordance, when compared to the answers of the 
surveys. All samples were positive for THC, except two oral fluid samples. 
 
IX. A sensitive, reproducible, precise, accurate and inexpensive GC-MS method was 
developed and validated to identify and quantify THC in whole blood samples. 
 
X. The proposed GC-MS method was successfully applied in the quantification of THC in 
real blood samples and shown to be appropriate for routine analysis. Blood samples 
represent the most used matrix with relevant importance in toxicological analysis. 
 
XI. Liquid-liquid extraction revealed to be the best extraction, allowing to obtain the best 
peak resolution and separation of the compounds.  
 
112 
 
XII. The use of exhaled air to analyze the concentration of ethanol revealed to be the best 
method.  However, the use of more than one matrix to quantify and qualify ethanol is 
essential for having a precise and better result. 
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2. Future Perspectives 
 
I.     Using screening methods, it was not possible to detect amphetamines and cocaine. 
The next step will be analyzing these samples with high sensitive methods. 
 
II. More samples should be collected for have a better perspective of drug abuse 
patterns in Coimbra. 
 
III. Some biological samples should be collected in accidental or injured individuals that 
recurred to the hospitals due to use of psychoactive substances. 
 
IV. Other psychoactive substances, including the new psychoactive drugs, should be 
identified and quantified in biological samples. 
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